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COUNTIES AND THE ASSOCIATED HPV PREVALENCE IN THIS POPULATION 
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ABSTRACT 
 
Objective: The purpose of this research study  was to examine the variation in 
healthcare providers’ behavior in recommending the Human Papillomavirus (HPV) 
vaccine to young male adolescents  (aged 11-12), middle male adolescents (aged 13-17) 
and late male adolescents (aged 18-26) in rural Southwest Georgia counties. This 
research also aimed to identify factors associated with providers’ behaviors concerning 
HPV vaccination recommendation to youth in various age groups.  
Methods: Upon IRB approval, secondary data were obtained from Albany Area 
Primary Care for a paper-based survey that was conducted in 2014 using a representative 
random sample of family physicians (n=12), pediatricians (n=6), and nurse practitioners 
(n=33). The survey had a response rate of 76% and the researcher employed descriptive 
statistics, paired t tests and analysis of variance (ANOVA) to describe the pediatricians’ 
(Peds), nurse practitioners’ (NPs/Nurses), and family physicians’ (FPs) recommendations 
to HPV vaccinations and the association of HPV prevalence in Rural Southwest GA.  
Results: Statistical testing and analysis show barriers such as healthcare 
providers’ and parents’ discomfort with the vaccination of pre-teens when it concerns a 
iv 
sexually transmitted disease, lack of awareness to the role that males play in the spread of 
HPV, absence of government mandates, and non-completion of the three-dose series of 
vaccination due to financial or logistical reasons. Provider specialty, age, ethnicity, and 
reported barriers were significantly associated with recommendations and association to 
HPV prevalence.  
Conclusions: Findings suggest missed HPV vaccination opportunities for 
adolescent males. Perceived barriers and support to HPV vaccination to providers may 
drive decisions about HPV vaccine uptake and completion of vaccination series. Findings 
also suggest the need for policy level interventions to increase HPV vaccination among 
US adolescent males. 
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CHAPTER 1 
INTRODUCTION 
Statement of the Problem  
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that is very 
common in the United States and that has been recognized as one of the most dangerous viruses 
as it is linked to various genital-related health problems in males (CDC, 2013). It is responsible 
for approximately 4,000 deaths annually within the country, and it is causally linked to cancers 
in areas such as the anus, genitals, and oropharynx (Schiffman et al., 2011). Each year, 9,000 
males in the United States contract HPV-related cancer (Dunne et al., 2014). In 2008, the vaccine 
targeting HPV, Gardasil™, entered the market and was targeted at males aged between 9 and 26 
years. The Centers for Disease Control Advisory Committee on Immunization Practices (ACIP) 
subsequently recommended vaccination of males between 9 and 26 years of age (CDC, 2013). In 
2009, another vaccine, Cervarix, was introduced into the market (CDC, 2010).  Despite a wave 
of federal and state policy initiatives aimed at promoting the vaccine’s use, a review of pertinent 
literature shows that there exist several barriers to the vaccination efforts. Research indicates that 
primary healthcare providers’ recommendations are a key factor for vaccine uptake among 
adolescents (Vadaparambil et al., 2011). The purpose of this paper is to describe healthcare 
providers’ recommendations to HPV vaccine to adolescent males. 
Current Situation   
The HPV virus is responsible for over 70% of cervical cancer cases. The HPV virus 
vaccination is currently recommended for girls 9 to 12 years of age and can also be administered 
for ages 13 to 26 (CDC, 2012). It is more effective if given before the girls’ first sexual contact. 
Absent vaccination, the only recommended and sure way of preventing infection with the HPV 
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virus is by total abstinence from sexual intercourse since the virus can be transmitted by the areas 
not covered by a condom even if a condom is used. As such, concerted efforts ought to be 
employed to avoid infection by vaccinating men as well as women (Shi, 2008). Currently the 
emphasis on HPV vaccination is skewed towards females, but this research proposes a balanced 
approach by targeting adolescent males for HPV vaccination as well. 
The many opposing opinions about HPV vaccinations can affect funding and research 
efforts concerning the effects of HPV among males (Siu, 2014). Recommendations by the Joint 
Committee on Vaccination and Immunization (JCVI) to introduce vaccination in boys have 
attracted criticism. The implementation of these JCVI recommendations would show that the 
male adolescent benefits from the vaccination. Boys would have minimal chances of contracting 
and spreading the HPV and HPV-related cancers. Among sexually transmitted diseases, HPV-
related infections are the most common in the US. In fact, it is estimated that 14 million US 
citizens are infected with this virus annually. The number of people suffering from the disease at 
any given time is about 70 million. Of the 150 identified strains of the HPV, 40 are carcinogenic 
and believed responsible for causing different types of cancers such as cervical cancer, as well as 
some less common types of cancers such as cancers of the anus and vagina (Stocker, Dehnert, 
Schuster, Wichman, & Delere, 2013). 
Two types of vaccines against HPV infections are currently available. These include 
bivalent (Cervarix) and quadrivalent (Guardasil) vaccines. These vaccines are totally effective 
against strains 16 and 18 which are the most potent causative agents of cervical cancer. Usually 
three shots of the vaccine are given to protect against HPV. These shots are administered as a 
series over a period of six months. Immunity against cervical cancer in women is provided using 
Cervarix and Gardasil. Gardasil is also effective in preventing genital warts, and vaginal, anal, 
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and penile cancers. Cervarix, however, is effective only against the strains of HPV that cause 
cervical cancers. The vaccines are effective when given to preteen boys and girls before they 
become sexually active. As such, the vaccine is currently recommended for preteen boys and 
girls (Vadaparampil et al., 2011).  
In addition to preteen girls and boys, the HPV vaccine is also currently recommended to 
teenage boys and girls who might not have been vaccinated at an earlier age. For males, the 
vaccine is recommended to be given through to the age of 21, but can be administered to males 
up to age 26. It is also recommended for men who engage in sex with other men, and for men 
with compromised immune systems. (CDC, 2012). Girls should be vaccinated up the age of 26. 
Vaccinations done after these ages have proven not to be effective (Vadaparampil et al., 2011). 
Purpose Statement   
This study will generate knowledge that will identify issues surrounding primary 
healthcare providers’ frequency of recommending the HPV vaccine to male adolescents aged 
11–26 in Southwest Georgia. 
Due to the burden of morbidity, mortality, and financial cost associated with this virus, 
the vaccine targeting HPV, Gardasil™, entered the market to target males aged between 9 to 26 
years. This also caused ACIP to recommend male immunization and vaccination against the 
virus targeting those between 9-26 years of age (CDC, 2013).  
This research examined the prevalence of providers’ recommendation of HPV 
vaccination to early male adolescents (aged 11-12), middle male adolescents (aged 13-17) and 
late  male adolescents (aged 18-26), as well as finding the factors associated with such 
recommendations, mainly in early male adolescents. The rationale for grouping of early, middle, 
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and late adolescents is due to the hormonal and physical differences that can be seen among 
these age groups. The CDC also recommends vaccination to start at 11-12 years of age.  
Concept of the Study  
The purpose of this study is to identify the effects of missed vaccination opportunities to 
a community’s health. Specifically, this researcher will seek to identify the relationship between 
the rate at which health care providers recommend HPV vaccine and the prevalence of HPV-
related diseases. In this, the effects of missed HPV vaccination opportunities will be revealed. It 
is expected that low rates of HPV vaccine recommendation will translate to high prevalence rates 
of HPV-related diseases among the population. The study will also look at the support and 
barriers healthcare providers encounter to recommending HPV vaccine (Gostin & DeAngelis, 
2007).  
The study will encompass at several factors that affect the rate at which healthcare 
providers recommend the HPV vaccine to their patients, and as  well as factors that contribute to 
missed vaccination opportunities including how attitudes, culture, and financial factors affect 
healthcare providers’ recommending or not recommending the vaccine. Therefore, this study will 
help identify solutions that will prevent the spread HPV-related infections (Gamble, Klosky, 
Parra, & Randolph, 2010).  
Terms and Definitions  
Health Care General community efforts to diagnose disease, treat disease, and prevent 
disease from developing.  It requires the input of both individuals and the 
community such as practitioners in allied health.  A healthcare venue 
allows the provision and accessibility to resources and conditions that 
foster individual health-promoting behaviors.  Health care refers to the 
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work done by primary, secondary, and tertiary care professionals, as well 
as public health. 
Primary Care  The first point of entry by a consumer of health (patient) into the 
healthcare delivery system.  This venue carries out public health 
functions of primary prevention, such as immunizations. While primary 
care providers normally treat individual patients, public health takes a 
population-health approach to disease prevention and interacts with 
policy makers that implement policies and programs within the 
healthcare delivery and utilization system.  
Health Behavior Health behavior refers to the actions of people and communities that 
result in social change, policy development, and health improvement. It 
aims either to prevent disease or to detect health problems. 
Primary 
Prevention 
Primary prevention is the ability to change an individual’s susceptibility 
to a health problem and also reduce the exposure to a causal agent. 
Public health is the primary prevention agency that is involved in 
epidemiological study in finding risk factors associated to the health of a 
population in general and possibly preventing or eliminating infections.  
Population–at-
risk 
Population-at-risk includes cohorts or persons who may contract a 
disease or develop a health problem. In this study adolescent males are 
the cohort or prospective population at risk.  
Quality of Care The Institute of Medicine (IOM) defines quality of care as safe, effective, 
patient-centered, timely, efficient, and equitable for individuals and 
populations. This research may improve access to preventive care by 
  
6
providing a better understanding of healthcare providers’ HPV vaccine 
recommendations. 
Research Setting  
Albany Area Primary Health Care, Inc. is an affiliate of the Georgia Association for 
Primary Health Care (GAPHC) and also a Federally Qualified Health Center (FQHC). It is 
located in Albany, GA, and provides healthcare services to rural and underserved communities in 
Southwest GA. 
Research Questions/Hypotheses  
The focus of this study will be on providers’ tendency to recommend HPV vaccine to 
early male adolescents (ages 11-12), as evidence indicates that this is the best age to introduce 
the HPV vaccine to ensure long-term effectiveness.  
Research Question A  
Are healthcare providers' rates of recommending HPV vaccination for males aged 11 to 
12 years old higher than those of males aged 13 to 17 years old? 
Null Hypothesis 
No difference exists between healthcare providers’ prevalence of recommending HPV 
vaccines to either early (ages 11-12) adolescent or middle (ages 13-17) adolescent males. 
Alternate Hypothesis 
A difference exists between the healthcare providers’ prevalence of recommending HPV 
vaccines to early (ages 11-12) adolescent and middle (ages 13-17) adolescent males. 
Research Question B  
Are healthcare providers' rates of recommending HPV vaccination for middle adolescent 
males (ages 13-17) higher than those of late adolescent (ages 18–26 years) males? 
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Null Hypothesis 
No difference exists between healthcare providers’ prevalence of recommending HPV 
vaccines to either middle adolescent or late adolescent males. 
Alternate Hypothesis 
Differences exist between healthcare providers’ prevalence of recommending HPV 
vaccines to middle adolescent and late adolescent males. 
Research Question C   
Are healthcare providers' rates of recommending HPV vaccination for early adolescent 
males (ages 11-12) higher than those of late adolescent males (ages 18-26)?  
Null Hypothesis 
No difference exists between healthcare providers’ prevalence of recommending HPV 
vaccines to either early adolescent (ages 11 -12) or late male adolescent males (ages 18-26). 
Alternate Hypothesis 
Differences exist between healthcare providers’ prevalence of recommending HPV 
vaccines to early adolescence (ages 11-12) and late adolescence males (ages 18-26). 
Research Question D     
Is there a variation in rates at which specialist healthcare providers’ (FPs, NPs, Peds) 
recommend HPV vaccines? 
Null Hypothesis 
No difference exists between specialist healthcare providers in their prevalence of 
recommending HPV vaccines to patients. 
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Alternate Hypothesis 
Differences exist between specialist healthcare providers in their prevalence of 
recommending HPV vaccines to patients. 
Research Question E   
Are healthcare providers' encountering perceived barriers in recommending HPV vaccine 
to adolescent males?  
Null Hypothesis 
No perceived barriers exist among healthcare providers’ prevalence of recommending 
HPV vaccines to adolescents males 
Alternate Hypothesis 
Perceived barriers exist among healthcare providers’ prevalence of recommending HPV 
vaccines to adolescents males 
Research Question F   
Is there variation in recommending rates by demographic characteristics of the provider?  
Null Hypothesis 
There is no variation in recommending rates by demographic characteristics of the 
provider. 
Alternate Hypothesis 
 There is variation in recommending rates by demographic characteristics of the provider. 
Delimitations    
This study uses secondary data obtained from a local federally qualified health center 
(Albany Area Primary Care-AAPC) that operates in several counties in Southwest Georgia. The 
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sample size is small and the responses may be based on regional socio-cultural and socio-
economic factors, along with other regional factors. 
Significance of the Study     
The quest to develop social awareness of the dangers of HPV has been assumed by 
different health organizations in the United States. The lack of awareness concerning the danger 
of HPV to men has led to the deaths of many unsuspecting people who succumb to various forms 
of HPV-related infections (Jemal et al., 2011). The burden of HPV-related illnesses among males 
is associated with primary care healthcare providers such as pediatricians (Peds), nurse 
practitioners (NPs), and family physicians (FPs) missing clinical opportunities to recommend 
HPV vaccination (Sudenga, Royse, & Shrestha, 2011). 
Because HPV can be the causative agent for many illnesses in males such as cancers of 
the anus and oropharynx, this study examines the relationship between missed vaccination 
opportunities and the prevalence of the various HPV-linked illnesses. The virus is highly 
transmissible directly through the skin, especially during sexual intercourse. Vaccination has 
proved to be an effective method by which development of HPV-related illnesses can be 
prevented. Therefore, individuals who receive the HPV vaccine are expected to have low 
probability of contracting HPV-related illnesses.  
The study also helps to compare the effectiveness of various HPV vaccines with that of 
other methods of HPV prevention. These methods include use of condoms, abstinence, and 
monogamy. According to the Youth Risk Behavior Survey (YRBS), in 2013, 46.8% of high 
school teenagers were sexually active, with 15% of these reporting four or more partners (CDC, 
2014). With the study revealing the various adverse consequences of missed vaccination 
opportunities, adequate measures will be taken to reduce instances of missed vaccination 
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opportunities. The study provides relevant information that can be used to curb HPV-linked 
illnesses (Gamble et al., 2010).  Mandatory HPV vaccination in Australia has greatly reduced the 
prevalence of genital warts in teenagers (Ali et al., 2013). Following this logic, it is likely that 
implementing HPV vaccination for adolescents in southwest Georgia would immediately begin 
to reduce the incidence of adolescent genital warts here as well. However, the benefits of 
reducing HPV-related penile, anal, and cervical cancers may take decades to be revealed (CDC, 
2013).  
Barriers that contribute to missed medical opportunities will be identified. The barriers to 
be examined include health workers attitudes, cultural barriers, compliance barriers, cost 
barriers, psychological barriers, and information barriers. Identification of these various barriers 
serves as the starting point in solving problems arising from missed vaccinations. The study will 
also identify ways through which these barriers can be overcome. Such solutions include 
adoption of relevant legislation and government policies, financial support from the government, 
and health workers informational drills (Goldstein, 2010). As such, the study directly suggests 
the solution to missed medical opportunities by identifying support that will enhance the goal of 
increasing primary healthcare providers’ rate of recommending HPV vaccination among 
adolescent males. 
By revealing the relationship between the likelihood of the healthcare providers to 
recommend HPV vaccine and the prevalence of HPV-related diseases in a rural community of 
southwest Georgia, this study can help to accomplish the public health goal of preventing poor 
health outcomes among the subject population (Gostin & DeAngelis, 2007). Basically, 
intervening and seeking to prevent a disease is the foundation of public primary health. In 
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addition, the study will generate knowledge which when disseminated to all the stakeholders 
could help bring about a healthier society (Gudeman, 2007).  
This research aligns with the functions of public health that are necessary to deliver 
essential health services. The study will therefore be important in monitoring the general health 
status of the community. It will identify community health problems by evaluating effectiveness, 
accessibility, and quality of both personal and population-based health services.  
The study also reinforces the need to develop policies and plans that will support 
individual and community health efforts. It will also inform, educate, and empower the 
community regarding HPV-related diseases. As such the study will add to the knowledge base 
regarding the HPV vaccine that is already available. This will help reduce the burden of HPV-
linked diseases which includes mortality, morbidity, and high financial costs. In the US, HPV-
related diseases are the most common sexually transmitted disorders. The CDC estimates that 
approximately $4 billion is expended annually to prevent and treat HPV-related diseases (CDC, 
2012). 
By revealing problems associated with missed vaccination opportunities, the study will 
enable public health authorities to actively promote the adoption of a preventive healthcare 
approach in dealing with HPV-related diseases. These efforts by public health authorities will 
create awareness in the community, and the number of young men seeking the HPV vaccine will 
increase. The public health authority will also encourage public health providers to administer 
the HPV vaccine to all young men seeking medical attention at their health centers.  
The study will be used as a road map that will set a guide for the development, 
implementation, and evaluation of HPV-related health issues. In addition, the study will be used 
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to understand the current behavior of healthcare providers in recommending HPV vaccines to 
young patients (Hoover, Carfioli, & Moench, 2000).  
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CHAPTER 2  
LITERATURE REVIEW 
Introduction   
HPV infection is considered the most common sexually transmitted infection, with half 
of the US population contracting it at some point in their lives. As it is transmitted through 
sexual contact, its incidence is very high in sexually active people, especially among men who 
have sex with other men. Statistically, 50% or less of heterosexual men, 61% of HIV-negative 
homosexual men, and 93% of HIV-positive homosexual men have HPV infection (Brewer, Ng, 
McRee, & Reiter, 2010).   
Human papilloma virus (HPV) replicates in the squamous epithelial cells of the cervix, 
anus, and tonsils. It can establish infection only in the keratinocytes of the skin and the mucous 
layer. Most infections are asymptomatic; however, in a few cases infection can lead to warts 
and/or cancers of the cervix, vagina, vulva, penis, oropharynx, and anus. Risk factors for 
infection include more than one sexual partner, use of oral contraceptives, smoking, and alcohol 
consumption. Use of condoms and circumcision can reduce HPV infections (Crosignani et al., 
2013).  
The majority of anal and penile cancers in men worldwide are associated with HPV 
infection. Gay men infected with HPV are 44 times more likely to get anal cancer. Gay men who 
are both infected with HPV and HIV positive are 60 times more likely to develop anal cancer 
(Newman, Logie, Doukas, & Asakura, 2013). Heterosexual men infected with HPV can increase 
their sexual partner’s risk of developing cervical cancer. Hence, protection from HPV for men in 
the form of vaccination becomes essential. However, for a number of reasons, vaccination is 
recommended only for females and not much priority is given to vaccination for males. A 
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number of school-based immunization programs have been put in place due to the alarming rates 
of cervical cancer; however, all of these programs are targeted to adolescent girls. Including boys 
in school-based vaccination programs is presently considered cost-ineffective and unnecessary 
(Newman et al., 2013).  
Preventing HPV infection can be accomplished largely through the use of two vaccines – 
the quadrivalent vaccine Gardasil (Merck), and the bivalent vaccine Cervarix 
(GlaxoSmithKline). The HPV risk-types that are targeted by Gardasil are HPV-16, -18, -6, and -
11, whereas Cervarix targets only HPV-16 and -18. 
Both of the vaccines have proven highly effective in preventing adenocarcinoma in-situ 
(AIS) in women; additionally, Gardasil also prevents genital warts, vulvar and vaginal 
intraepithelial neoplasia grades 1-3, and high-grade anal disease in men. However, Cervarix is 
cheaper compared to Gardasil and also offers longer protection – 8.4 years, compared to 6.4 
years for Gardasil. Studies have also found that Cervarix can generate higher antibody titers 
compared to Gardasil. Despite all this data in favor of Cervarix, Gardasil is preferred due to its 
wider range of protection (Ma et al., 2012). The safety and efficacy of both vaccines has been 
very well documented, and both afford protection against 80% of all cervical cancers (Hung, Ma, 
Monie, Tsen, & Wu, 2008). 
Critical factors in HPV vaccination include immunogenicity, safety, and clinical 
significance (Crosignani et al., 2013). The current option for HPV vaccination in men is the 
quadrivalent vaccine, Gardasil, which has been licensed for use in men since 2009. In 2011, 
Gardasil was approved by the ACIP for use in male adolescents aged 11-21 years for the 
prevention of genital warts and anal cancer. This vaccine has been proven to be more than 90% 
effective in the prevention of HPV infection (Newman et al., 2013). 
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The literature review on HPV vaccine uptake in male adolescents shows the important 
association between barriers and supports within primary prevention. Research shows that the 
primary prevention of HPV among adolescent males largely depends on the attitudes and 
behaviors of primary healthcare professionals, parents, and the adolescent males themselves. 
Barriers in any form at any level can lead to hindrances in the proper use of HPV vaccination for 
men. The primary challenges that exist for healthcare professionals include individual, 
ecological, and cognitive barriers such as doubt, confusion, and concerns regarding vaccine 
uptake. In addition, organizational barriers might also exist due to ignorance or financial 
restrictions. Restrictions can also come from the society at large in terms of capital and financial 
support. Primary healthcare professionals play a very important role in vaccine uptake by 
providing appropriate knowledge, recommendations, and resources. 
As the nature and extent of these barriers has become apparent through a number of 
surveys conducted by various public health organizations, a number of organizations have 
extended their support to overcome these barriers. The greatest and most important barrier is 
cost, and so support in this direction has resulted in a lot of countries offering the HPV vaccine 
free of charge to the target population. Primary healthcare providers also play a very important 
role in recommending the vaccine to eligible patients and addressing their questions regarding 
HPV infection and vaccination. Other sources of support include state policies, regulatory 
bodies, and the U.S. National Vaccine Plan. In the age of technology, maintenance of electronic 
health records and ensuring their security and privacy also go a long way in encouraging HPV 
vaccination. 
The theoretical framework used in this study includes the social cognitive theory (SCT), 
social ecological model (SEM), and the public health model. The SCT helps generate an 
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interpersonal collective effort in producing the desired result (Bandura, 2001). In the SEM, 
health-related behaviors are studied with respect to physical, social, and policy aspects (Baral, 
Logie, Grosso, Wirtz, & Beyrer, 2013). The public health model promotes assessment, policy 
development, and assurance of public health programs such as vaccination. In addition, it takes 
into consideration the host, the agent causing the infection, and the environment in which the 
agent thrives (Horvath, Misra, Epner, & Cooper, 2014). A combination of these models has been 
used as an evidence-based framework for prevention of HPV infections. 
Guiding Theory and Framework   
Health behavior theories are pertinent in offering a framework for guiding the 
development of such an intervention. The SCM were selected to guide this intervention within 
interpersonal level within the social ecological model.   With the findings of this research, public 
health authorities will be in a position to develop outreach programs, campaigns, and policies 
that will eliminate the factors identified and so enhance the efficiency of public health 
organizations in delivering the HPV vaccine to male adolescents (Dunne et al., 2011). 
 It is ethical for primary healthcare providers to create awareness in their workplace to 
help to prevent HPV-related morbidity and mortality among adolescent males. Previous studies 
have focused on the roles of healthcare providers in helping young women to understand the 
preventive healthcare they require (Weiss et al., 1997). This study highlights these past findings 
and adds to the information already available.  
These theories were used as roadmaps that help in guiding the development, 
implementation, and evaluation of this research study. In addition, they aid in comprehending 
current behavior of healthcare providers regarding their inclination toward HPV vaccine 
recommendation to adolescent males (Glanz, Rimer, & Viswanath, 2008). The social cognitive 
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theory was used to understand the interpersonal level of healthcare providers’ inclinations in 
recommending the HPV vaccine for adolescent male clients.  These theories are embedded 
within the public health framework and context.   
The Social Cognitive Theory (SCT) and the Social Ecological Model (SEM)   
The SCT (Rotter & Bandura, 1996 as cited in Glanz, Rimer, & Viswanath, 2008) is built 
on the earlier social learning theory (Miller, Dollard, & Rotter, 1954 as cited in Glanz, Rimer, & 
Viswanath, 2008).  The SCT is a dynamic theory that emphasizes reciprocal determinism—a 
concept that recognizes that primary healthcare providers, the healthcare industry, and the 
regulatory environment are all interconnected. According to Bandura, the primary healthcare 
provider’s behavior will be influenced by vicarious experience or observing the behavior of other 
healthcare providers (Andresen et al., 2010 as cited in Glanz, Rimer, & Viswanath, 2008). 
The SEM also suggests that there are associations among healthcare providers, 
community organizations, and societal policies. Therefore, providers’ inclinations in 
recommending vaccination among male adolescents can be influenced by various constructs 
such as collective efficacy, observational learning, incentive motivation, facilitation, self-
regulation, and policies (Glanz et al., 2008). As such, this intervention will also seek to identify 
support that will enhance the goals of primary healthcare providers in recommending HPV 
vaccination among adolescent males. 
Employing the Public Health Framework in the Research   
Understanding the relationship between a healthcare provider’s inclinations in 
recommending HPV vaccines and the rural community they serve is important within this 
research and could be used to accomplish the public health goal of preventing poor health 
outcomes among underserved and rural communities in southwest Georgia. Public health’s 
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primary prevention objective is to intervene and seek to prevent disease before it begins. That is 
a core tenet of this research in missed clinical opportunities for providers to recommend HPV 
vaccination in southwest Georgia.   
This study is pertinent to the public health framework because it aligns with public 
health’s core functions that are necessary to maintain public health (assessment, policy 
development, assurance) and the deliver essential public health services that include: 
-Monitoring health status to identify community health problems 
-Diagnosing and investigating health problems and health hazards in the community 
-Informing, educating and empowering people about health issues 
-Mobilizing community partnerships to identify and solve health problems 
-Developing policies and plans that support individual and community health efforts 
-Enforcing laws and regulations that protect health and ensure safety 
-Linking people to needed personal health services and assuring the provision of health 
care when it might otherwise be unavailable 
-Assuring a competent public and personal healthcare workforce 
-Evaluating the effectiveness, accessibility, and quality of personal- and population-based 
health services. 
(CDC, 2013) 
The study also will add to the knowledge base concerning HPV vaccinations that will 
help to reduce the burden of HPV-related diseases in terms of mortality, morbidity, and financial 
cost.  Human papilloma virus is the most common sexually transmitted disease in the US and 
causes an estimated 26,000 HPV-cancer related illnesses in the each year.  The CDC estimates 
the US spends $8 billion on the prevention and treatment of HPV-related diseases (CDC, 2013).  
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Public health authorities are actively targeting the adoption of a preventive healthcare 
approach to deal with serious diseases such as HPV-related cancers. The campaign to create 
awareness about HPV and its effects on human health has received a great response in terms of 
the number of males looking to get HPV vaccinations. Primary healthcare providers are 
encouraged to ensure that they recommend the vaccine to all young males who seek medical 
attention in their facilities. Greater awareness about the virus and HPV-related cancers is one of 
the most reinforced messages in the campaign for cancer prevention. The Centers for Disease 
Control’s Advisory Committee on Immunization Practices (ACIP) is keen to promote the 
delivery of the vaccine for all young adolescents in the United States. Cancer is not selective 
based on social class; thus, an effective program must be developed to solve the numerous 
barriers to reaching people in these rural areas with the HPV vaccine (Caskey, Lindau, & 
Alexander, 2009). 
This research provides a framework with which to identify barriers and support the increase of 
provider recommendations of HPV vaccination in rural areas (Brewer et al., 2011).  It is 
important for primary healthcare providers to create relevant awareness in their workplace to 
help to prevent HPV-related infections among adolescent males. Previous studies have focused 
on the roles of providers in helping young women to understand the preventive healthcare they 
require (Weiss et al., 1997). This study will highlight these past findings and aims to add to the 
information already available. 
Although two HPV vaccines (Gardasil and Cervarix) entered clinical trials in the 1990s, 
literature on the subject of this research remains inadequate. Most of the literature available 
concentrates on vaccine uptake in females. One reason for this could be that female vaccination 
is given higher priority than male vaccination. This study concentrates on the attitudes and 
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barriers perceived by healthcare professionals and parents that hinder HPV vaccination of 
adolescent males, and the supports available for overcoming these barriers. 
Barriers Related to HPV Vaccination   
The various barriers related to HPV vaccination in adolescent males are listed below. 
Informational Barriers    
The greatest barrier to HPV vaccination is ignorance – lack of information and education 
among adolescent males, their parents, and healthcare professionals (Chan, Cheung, & Chung, 
2007; Hoover et al, 2000). Most people are unaware that HPV infections can be dangerous and 
are directly associated with cancers such as penile, oropharyngeal, and rectal.  
In one study, Chinese mothers of adolescent children were given an information 
pamphlet to analyze if there was a change of opinion towards HPV vaccination after obtaining 
the information from the pamphlet. Before reading the information pamphlet, 32% of women 
were found to support HPV vaccination for their children. After reading the pamphlet, however, 
56% of the women surveyed changed their minds about HPV vaccination from disagreement or 
indecision to agreement. Out of these women, 79% accepted that their earlier indecision or 
disagreement towards HPV vaccination was due to a lack of knowledge about HPV infection and 
its potential risks. The second most common reason for not being supportive of HPV vaccination 
was due to fearing the potential side effects of the vaccine which indirectly stem from lack of 
information (Chan et al, 2007). 
In another study among French women, 76.2% were aware of HPV vaccination; 
however, only 16.9% were aware that HPV infection in women could lead to cervical cancer. (In 
France, cervical cancer is the tenth most common cancer in women.) Among the women 
surveyed, only 54.3% were in favor of HPV vaccination, 0.9% were against it, and 37.2% were 
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undecided about the necessity for vaccination. Also, 14.1% of the participants said that they 
would rely on their healthcare provider’s judgment. The survey showed that few people were 
aware of the recommended ages and the target population for HPV vaccination. Further, only 
16% said that they had obtained information about the vaccine from their physician; 54.7% had 
heard about it on television (Haesebaert et al., 2012). 
In southern Australia, out of 2,000 people questioned, only 40 people were aware of the 
cause of HPV infections (Marshall, Ryan, Roberton, & Baghurst, 2007). Another study found 
that about 33% of parents in the Netherlands were aware of HPV, and only 15% were aware of 
the link between HPV and cancer (Lenselink et al., 2008). A survey of 37 healthcare 
professionals in New Mexico found that lack of knowledge about HPV prevented them from 
counseling parents about HPV vaccination.  
In the rural setting of Appalachian Ohio, among 25% of the people surveyed in this 
region, lack of knowledge was a very important barrier to HPV vaccination (Oldach & Katz, 
2012). 
Among 10th grade students in Germany, 63.6% of the children knew that HPV infection 
was sexually transmitted. However, only 41% of the children had received the recommended 
three doses of HPV vaccine. It was observed that children who had received at least one dose of 
the vaccine were more supportive of HPV vaccination than children who had not received even 
one of the three doses of HPV vaccine. The study also found that the information status about 
HPV vaccination was lower among boys than girls. This was thought to be due to the fact that 
educational campaigns about HPV vaccination are targeted towards girls rather than boys and 
hence boys were unaware of the dangers and risks of HPV infection. It was also seen that 
vaccinated individuals were more knowledgeable about HPV infections than unvaccinated 
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children, and this was thought to be due to information provided to the child and his/her parents 
about HPV infections prior to vaccination. The preferred sources of information about HPV 
infections among the children surveyed were their healthcare provider and their parents. It is 
ironic to note that the most common reason for not being vaccinated was reported to be 
dissuasion coming from their physicians and/or parents. Hence, educational campaigns should be 
targeted towards healthcare providers and parents of adolescent children (Stocker, Dehnert, 
Schuster, Wichman, & Delere, 2013).  
A study among male college students found that most relied on information about HPV 
from commercials or advertisements or obtained information from their friends, or relied on 
news programs and health education programs. The most common sources were considered to be 
the television and the internet. Hence, the sources of information for most people about HPV 
infection and potential risks are not reliable. The college students were found to be highly 
uninformed about HPV and only 4.5% expressed concerns about acquiring HPV infection (Katz, 
Krieger, & Roberto, 2011). 
In a study conducted among females attending Florida State University, knowledge about 
HPV infection was found to be moderate. Factors that affected the variation in HPV knowledge 
among these people were found to be Latin ethnicity, incidence of premarital sex, number of 
sexual partners, HIV testing, and history of cervical dysplasia. Sexually active people with more 
than one sexual partner had more knowledge about HPV than those who are opposed to pre-
marital sex. Television commercials also worked positively to provide information about HPV 
vaccination. It was observed that 84% of the participants were aware of the link between HPV 
infection and cervical cancer. However, only 30% of the participants were aware that HPV 
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infection could also lead to genital warts. Sixty percent of the participants also incorrectly 
thought that HPV infection could lead to ovarian cancer (Gerend & Shepherd, 2011). 
The acceptability levels of HPV vaccination among people in sub-Saharan African 
countries were found to be high in a study conducted there; however, knowledge about HPV 
infection and vaccination was low. Given that cervical cancer in women is among the leading 
causes of mortality in this region, the reach of vaccination programs is surprisingly low (Perlman 
et al., 2014). A lack of knowledge among the people in this region has resulted in an overall 
negative opinion regarding the safety of the vaccine, along with concerns regarding possible side 
effects. Due to serious concerns about the health of women in this region, a number of strategies 
have been proposed to educate the people in this region thereby increasing acceptability levels. 
Some of the proposed methods include HPV vaccination pilot programs, clinic- and school-
based vaccination programs, community outreach programs in churches, sensitization 
campaigns, educational campaigns to targeted groups such as doctors, nurses, midwives, and 
healthcare workers, and awareness through social media and mass media (Perlman et al., 2014). 
It is heartening to note that, according to a study conducted in Vietnam, a large portion of 
the population there is supportive and convinced that HPV vaccination is beneficial. The study 
also found that the people largely trusted information provided by educational campaigns 
conducted by the government, as they believe that the government would do nothing to harm 
people’s health (Cover et al., 2012). 
According to a 2012 study conducted by Bartolini, Winkler, Penny and LaMontagne in 
Peru, if adequate information was available to the people from credible sources, most of the 
parents did get their adolescent children vaccinated. Sources that had the most effect on the 
parents’ decision-making process were teachers and healthcare providers. This clearly 
  
24
demonstrates that information campaigns will go a long way in ensuring HPV vaccination of the 
entire target population (Bartolini et al., 2012). 
Research has shown that a very important factor in changing the mindset regarding HPV 
vaccination is community sensitization meetings with parents. This has been proven to work 
better in rural areas than in urban areas. These meetings were found to be intense educational 
sessions for the parents, and they also found good information in the consent forms. These 
meetings also allowed them to ask questions, and to voice their fears and concerns. Some people 
said that they heard about the vaccine for the first time in these meetings. A few others also 
reported that they had made a decision to get their children vaccinated against HPV based on the 
discussion that took place in the meeting (Bartolini et al., 2012). 
Another example of an information campaign about HPV vaccination is a multi-level, 
multimedia communication campaign implemented in Peru via radio stations, the local Catholic 
Church, press, television, and posters and banners used in health facilities and schools. Many 
people reported that, after having seen or heard these news items, they decided to go ahead and 
have their children vaccinated (Bartolini et al., 2012). 
Lack of proper information about HPV vaccination can hugely affect the efforts of the 
government and health organizations to protect against HPV infections. Thus, educational 
campaigns and interventions about HPV have been highly recommended for parents and 
healthcare professionals. 
Safety and Efficacy Barriers    
Safety concerns about the HPV vaccine are another important barrier for both parents and 
healthcare workers. In a study conducted in the Netherlands, 1,367 participants had concerns 
about the safety and efficacy of the vaccine. This concern acts as a huge barrier to vaccine uptake 
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(Korfage, Essink-Bot, Daamen, Mols, & van Ballegooijen, 2008). Another study involving 
pediatricians found that the same concern prevented them from providing appropriate counseling 
to parents (Kahn & Bernstein, 2005). This concern could also be a byproduct of a lack of 
information as studies sufficiently prove the safety of HPV vaccines such as Gardasil (Gudeman, 
2007). Concerns about the vaccine are also centered on potential side effects (Gerend, Lee, & 
Shepherd, 2007; Marshall et al., 2007; Woodhall et al., 2007).  
It is readily apparent that these concerns indirectly stem from lack of information. This is 
true because the safety and efficacy of both HPV vaccines (Gardasil and Cervarix) have been 
proven time and again through studies and clinical trials. It has been shown that both of these 
vaccines prevent infection with HPV types 16 and 18, which are responsible for 70% of all 
cervical cancers. Data from clinical trials show that these vaccines are 90-100% effective in 
preventing the formation of precancerous cervical lesions due to infection with HPV types 16 
and 18 (Fernandez, Allen, Mistry, & Kahn, 2010). 
Clinical trials of both vaccines conducted in different parts of the world have shown that 
the clinical endpoints include cervical intraepithelial neoplasia (CIN) 2/3, adenocarcinoma in-
situ (AIS), and anogenital warts, which are considered to be precursors to cervical cancer. Data 
from a large number of international, randomized clinical trials prove the immunogenicity and 
efficacy of both these vaccines. Gardasil is also shown to prevent anogenital disease caused by 
HPV types 6 and 11. Clinical trials and post-marketing safety monitoring measures have shown 
that both the vaccines are reasonably safe and well-tolerated. This has been further supported by 
data from the Center for Disease Control and Prevention (CDC) in the US, and the World Health 
Organization (WHO) Global Advisory Committee on Vaccine Safety. The CDC has also 
conducted post-licensing studies to evaluate the safety of Gardasil, and no adverse events have 
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been seen to occur due to the vaccine. Despite these studies and trials, there are still a great 
number of people who have concerns about the safety of these vaccines, and hence refrain from 
having their children vaccinated (Fernandez et al., 2010). 
Studies have effectively shown that because both of the HPV vaccines, Gardasil and 
Cervarix, are comprised of non-infectious virus particles, the vaccine in turn is non-infectious 
and safe. Both vaccines have been shown to elicit strong antibody responses, thus proving their 
efficacy. It has been noted, however, that the vaccines are not very effective in people who have 
already acquired HPV infection through sexual contact. Hence, it is important that children get 
vaccinated against HPV before they reach sexual maturity. Regarding safety of the vaccine, 
studies show that the most common side-effects after HPV vaccination include erythema, pain at 
the injection site, and swelling. One serious consequence of HPV vaccination was that a small 
number of women who became pregnant within 30 days of vaccination underwent spontaneous 
abortion. If a woman gave birth after conceiving within 30 days of vaccination, the children were 
found to have congenital abnormalities. This further reinforces the fact that adolescents should 
get vaccinated against HPV before commencing sexual intercourse (Moscicki, 2008). 
Another concern for parents was that it would send the wrong message to their children 
regarding sexual practices or age for initiation. A study conducted among healthcare providers in 
Texas found that about 50% parents were averse to HPV vaccination due to concerns regarding 
safety, negative media reports, and the concern that vaccination would encourage premarital 
intercourse (Fernandez et al., 2010). 
Among 10th grade students in Germany, about 30.8% of the participants were 
unvaccinated due to concerns about the vaccine’s safety and potential side effects. About 9% of 
the participants also considered the HPV vaccine to be relatively new and that more research was 
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needed to explore its safety (Stocker et al., 2013). In France, almost 55% of the participants were 
averse to HPV vaccination due to concerns about possible side effects and the newness of the 
vaccine. Another factor was distrust that stemmed from a controversy, also in France, regarding 
a link between hepatitis B vaccination and multiple sclerosis after a mass hepatitis B 
immunization campaign in 1994 (Haesebaert et al., 2012). Similar trends are observed in high-
income countries such as the UK and the US where people have trust issues regarding a 
vaccine’s safety in addition to questioning the motives of pharmaceutical companies and 
governmental health agencies in promoting vaccination. People also fear that the vaccine will not 
be effective long term. These people tend to have issues with all vaccines and find it difficult to 
come to terms with the fact that a vaccine is an inactive form of an infectious organism (Ferrer, 
Trotter, Hickman, & Audrey, 2014). 
On the bright side, among the people of Denmark, attitudes towards HPV vaccination 
were mostly positive and arose from a general confidence in the safety and efficacy of the 
vaccine. However, a lot of parents expressed the need to have more information about the action 
and safety of the vaccine before proceeding with vaccination. A majority of the parents were not 
worried about vaccination encouraging unsafe sexual practices as they believed that both men 
and women were responsible for taking care of their health and protecting themselves from 
sexually transmitted diseases (STDs) (Mortensen, 2010). 
In Hong Kong, 51.2% of the people regarded vaccine safety as an important criterion for 
choosing a vaccine. The other criteria were strength of protection, life-long immunity, and a 
good antibody response. Even among physicians, the same trend was observed. As many as 
78.6% of adolescents reported that their parents refused to get them vaccinated against HPV due 
to safety concerns (Wong, Lee, Ngai, Chor, & Chan, 2013). 
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In Canada, only 65.1% of parents agreed to have their children vaccinated against HPV, 
as opposed to 85% who agreed to vaccination for hepatitis B and meningitis C. Almost 50% of 
those who had agreed to HPV vaccination said that their main reason for consent was belief in 
the effectiveness of the vaccine. On the other hand, about 33% of the parents who were against 
HPV vaccination said that their main reason for not agreeing to have their children vaccinated 
was concerns regarding the safety of the vaccine. About 46.3% of the parents who were against 
vaccination also said that if they had more data about the safety of the HPV vaccines, they would 
be able to make an informed decision regarding vaccination (Ogilvie et al., 2010). 
This barrier has a lot of implications for HPV vaccine policies, as it is not a financial or 
organizational barrier that can be dealt with on a single level. Although vaccine programs are 
fully funded as a part of school-based immunization programs in a many countries, almost 35% 
of the parents choose not to have their children vaccinated due to safety and efficacy concerns. In 
a study conducted in Manchester, UK, parents identified vaccine safety as a major factor for not 
supporting HPV vaccination. This trend is true for a large number of regions around the world 
according to studies conducted in these places (Ogilvie et al., 2010). 
Efforts to overcome this barrier have been implemented in a number of places. One 
example is British Columbia, Canada, where vaccine education programs were conducted to 
address vaccine safety and efficacy issues via a number of platforms such as the 
www.immunizeBC.ca website, distribution of two sets of DVDs highlighting the safety of HPV 
vaccines—one set for parents and the other set for adolescents—and pamphlets, brochures, and 
local information sessions for both parents and healthcare providers emphasizing the safety and 
efficacy of both HPV vaccines. Also, the Canadian National Advisory Committee on 
Immunizations was involved in strongly recommending this vaccination for adolescents. Despite 
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these efforts, it is distressing to note that a lot of parents were undecided about HPV vaccination 
and reported that they needed more information to come to a decision (Ogilvie et al., 2010). 
Psychological Barriers    
Psychological barriers are comprised of personal or emotional discomfort regarding HPV 
vaccination. These barriers can be from the side of the healthcare professionals regarding 
interactions with parents or guardians (Dempsey & Davis, 2006; Kahn & Bernstein, 2005; 
Sussman et al., 2007), or from the side of parents and adolescent males regarding the 
encouragement of promiscuity due to HPV vaccination (Marshall et al., 2007; Woodhall et al., 
2007). Such barriers could also arise from lack of knowledge or cultural barriers of the patients. 
In Ireland, an attempt to understand the general practitioners’ and nurses’ attitudes 
towards recommending the HPV vaccine to their patients found that a number of concerns 
inhibited them from doing so. Some of those concerns included starting a discussion about HPV 
infection with their female patients, appropriateness of the situation in which to offer HPV 
vaccination, and addressing patients’ questions regarding HPV. This can hugely affect the 
attitudes of the patients towards HPV vaccination for women. Their GP’s attitude influences 
their own prevention behaviors. Most healthcare providers surveyed said that it was easier to talk 
about HPV with their patients if the discussion was indirectly started by them in terms of Pap 
smear testing or risk factors for cervical cancer. These providers rarely performed a routine HPV 
tests on their patients. Also, the providers seemed to be influenced by gender differences, 
thinking that only women should perform an HPV test for another woman (McSherry et al., 
2012). 
According to a study, a lot of practitioners consider the topic of HPV to be “sensitive” 
and “awkward” because it relates to sexual practices and the prevention of STDs. There were 
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concerns about embarrassment and awkwardness with their patients. This made the practitioners 
beat around the bush with regards to this topic or avoid it altogether. Another factor was patients’ 
reluctance to discuss the topic due to social influences. They were also worried about the 
consequences if the topic of HPV was raised and the patients might subsequently avoid Pap 
smear testing altogether. A number of nurses said that if they raised the topic of HPV with their 
patients, they would consider it as passing judgment on their sexual practices and this would be 
considered professionally inappropriate. The providers’ concerns about the appropriateness of 
the topic might not be completely without reason as a survey conducted in Ireland found that 
women were reluctant to go for Pap smear testing as they considered it a sign that they were 
sexually active. Also, when women found out about the link between HPV and cervical cancer, 
they “were shocked, angry, and felt that this was a ‘secret’ that the medical community had kept 
from them” (McSherry et al., 2012). 
A study that aimed to examine the effects of gender bias on the decision to go for HPV 
vaccination found that women who are less educated, older, uninsured, homeless, migrants, 
lesbians, obese, or have language problems are less likely to go for Pap smear testing. In China, a 
woman is considered inferior to a man, and so women are generally deprived of medical health 
facilities and regular checkups. Also, women who are lesbians often have to deal with the fear of 
discrimination and hence, shy away from taking medical advice or initiating discussions about 
the risks of unhealthy sexual practices. A survey in Canada found that lesbians have a much 
poorer health status as compared to heterosexual women. This result is true for the US and the 
UK as well: “In the UK, lesbian women are more likely to avoid screening than heterosexual 
women, and more likely to have never attended screening than American lesbian women.” In the 
UK, it has been seen that negative Pap smear test results can lead to stigma, guilt, and 
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embarrassment, and might work negatively in having the patient go for treatment (Brankovic, 
Verdonk, & Klinge, 2013). 
Another study analyzed the perceptions and beliefs of mothers of 11 to 12-year-old 
children had concerning whether or not to get an HPV vaccination. Factors influencing this 
decision included parents’ experiences and beliefs regarding vaccination in general, discussions 
with healthcare providers, friends, and family members regarding HPV infection and 
vaccination, and information provided by media about HPV vaccination. However, it was found 
that “mother’s health-related beliefs and experiences were the most frequently noted factors in 
the decision to vaccinate daughters.” Regarding the age group for which the vaccination is most 
appropriate, one mother noted that “I feel if it’s gonna protect her when she becomes sexually 
active, do it now. Because with today’s day and age you never know when they’re going to start 
having sex.” Other positive influences came from a family history of cancer, HPV infection, or 
other STDs (Griffioen et al., 2012). 
Factors that affected the uptake of HPV vaccination included perceptions about what 
others thought about HPV vaccination, discussion with adolescents regarding HPV infection and 
its mode of transmission, knowledge about a patient’s sexual history, and discomfort in talking 
about HPV with female patients. The study found that about 10% of pediatricians were unlikely 
to recommend the vaccine to their patients, and only 46% of the providers were ready to 
administer the vaccine to their patients. Factors that help patients choose to get vaccinated 
against HPV include HIV testing in the past, having multiple sexual partners either in the past or 
present, a family member suffering from cancer, and level of acceptance of the vaccine in the 
family (Gamble et al., 2010). 
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Another study found a relationship between emotional responses and societal influences 
and the decision to get vaccinated against HPV. Most of the participants said that their emotional 
responses on hearing about HPV varied from shock to concern, depending on how the 
information was given to them. They seemed to think that talking about vaccination against HPV 
was more likely to invoke positive reactions than dwelling on the link between HPV and cervical 
cancer. They thought that the general perceptions and beliefs of the society regarding HPV 
vaccination also depended on how the information was put across to them. This was because 
talking about vaccination provided them with a way to prevent cervical cancer in the future 
rather than judging their current sexual practices and scaring them about HPV infections, STDs 
and cervical cancer (McRae, Martin, O’Leary, & Sharp, 2014). 
Other factors that were important in having the practitioners discuss HPV with their 
patients included their concerns about the safety of the vaccines, having or not having daughters, 
negative media publicity about HPV, personal thoughts and beliefs about vaccination in general 
and HPV vaccination in particular, embarrassment in not being able to answer patients’ questions 
correctly, and considering it inappropriate to talk about sexual issues with their patients 
(McSherry et al., 2012). 
Among the Dutch, the attitudes and perceptions towards HPV vaccination were 
influenced by factors that included religious beliefs, perception of risks associated with 
vaccination, expectations of either positive or negative outcomes, anticipation of regret after 
vaccination, opinions about alternative medicine, and confidence levels in the authorities 
promoting HPV vaccination. Beliefs such as “The HPV vaccination was only introduced because 
the pharmaceutical industry will earn a lot of money from it,” “My daughter is too young to 
receive the HPV vaccination,” and “My daughter does not need to get the HPV vaccination if she 
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is already sexually active” had a very strong influence on peoples’ decision regarding HPV 
vaccination. The perceptions and beliefs of friends, general practitioners, physicians, nurses, 
people from the municipal health service and the Ministry of Health, spouses, parents, and other 
family members mattered when deciding whether or not to vaccinate children against HPV 
(Keulen et al., 2013).  
A major cause for concern is parental beliefs that getting their child vaccinated against 
HPV will encourage risky sexual behaviors. Apart from this, conservative religious views, moral 
issues about sexuality, not considering their child to be at risk for acquiring HPV infection, 
previous negative experience(s) with vaccination, and parent-child communication about safe 
sexual practices also influence parents’ decision to get their children vaccinated against HPV 
(Gamble et al., 2010). 
All these studies point toward an emerging need to provide support to healthcare 
providers in discussing HPV infection and vaccination with their patients. Efforts should be 
targeted towards both male and female healthcare providers and should help them in discussing 
HPV with their female patients, recommending HPV vaccination in appropriate cases, and 
answering patients’ questions about HPV (McSherry et al., 2012). 
Cultural Barriers   
Cultural barriers such as race, ethnicity, socioeconomic status, education levels and 
health insurance status can stand in the way of HPV vaccination (Sussman et al., 2007). 
According to Daley, “Across racial/ethnic groups, factors associated with vaccine acceptance 
among men include knowledge of HPV, perceived threat, and perceived barriers to HPV 
vaccine” (Daley et al., 2011). 
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This barrier is important because studies show that Black and Hispanic people are more 
often diagnosed with HPV-related cancers than people belonging to other ethnicities. It has been 
noted that Hispanic people have stronger intention to go for HPV vaccination than non-Hispanic 
people; however, very few Hispanic people have access to a healthcare facility where they could 
actually get vaccinated. Also, after informational sessions, about 43% of the people belonging to 
minority groups said that they were unable to grasp or comprehend the information completely. 
A survey conducted in 2007 showed that only 1% of Hispanic women had acquired at least one 
dose of the vaccine (Daley et al., 2011).  
A study of people of Hispanic origin in New Mexico showed that healthcare 
professionals had to consider cultural beliefs of the patient with respect to HPV infections and 
vaccination before recommending the vaccination to them (Vanslyke et al., 2008). For example, 
most Hispanics, as a result of their cultural beliefs, do not use condoms during sexual intercourse 
and thus can expose their partner to the risk of HPV infection. Another study found that 
healthcare professionals also had concerns regarding their patients’ strong religious views or 
beliefs about healing or general distrust of healthcare facilities (Tissot et al., 2007).  
A very important factor that can serve as a barrier to HPV vaccination is social beliefs 
and values, particularly those relating to sexual practices and behaviors. These concerns were 
found to influence healthcare providers in recommending the vaccine to parents of adolescent 
children. On one hand, they were more inclined to recommend the vaccine if they suspected 
people of belonging to a group where sexual intercourse with multiple partners was common; 
however, they seemed to be reluctant to discuss sexual issues with their more conservative 
patients. This also acted as a deterrent to many parents who did not want to discuss sexual issues 
with their children or who did not want to accept that their children will soon become sexually 
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active and the importance of protecting them against sexually transmitted diseases (STDs) 
(Ferrer et al., 2014). 
An interview with a school nurse in Sweden revealed that when people belonged to a 
strict cultural background where premarital sex is taboo, it was difficult to talk to them about the 
dangers of intercourse with multiple partners. They felt that if this vaccination was given to their 
children, they would get the wrong signal regarding sexual practices and this would encourage 
them to try intercourse before marriage. This is also true for religious faiths that are strictly 
against premarital sex and hence do not consider this vaccination necessary. In these scenarios, a 
concern for adolescents is that if they talk about this vaccination, their parents and family 
members might think that they are having illicit sexual relations (Ferrer et al., 2014). 
Women in Hong Kong also have similar concerns about HPV vaccination and premarital 
sex. They also see the HPV vaccine as a potential threat to the health of their children and 
consider it unnecessary. This attitude also arose due to the lack of fruitful discussions regarding 
the necessity and efficacy of the vaccines with their healthcare providers (Siu, 2014). 
The perceptions of African Americans toward HPV vaccination included a number of 
barriers that prevented them from taking the step. However, the fear of their children initiating 
sexual intercourse after vaccination was not very prominent. They believed that children will 
engage in sexual relations whenever they feel ready and it has nothing to do with their 
vaccination status. Religious issues were also not a problem here as they felt that religion had its 
own place in one’s life; however, it should not bear upon the decision to take care of one’s health 
(Thompson, Arnold, & Notaro, 2012). 
The attitudes of Latinas towards HPV vaccination are important because Latinas usually 
present with higher rates and severity of cervical cancer compared to non-Latinas. It was found 
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that only 59% of the participants thought that HPV vaccination could effectively prevent HPV 
infection. The Latinas’ lack of knowledge and awareness about HPV could be attributed to 
“lower education, low English language acculturation, and lack of exposure to media messages” 
(Luque et al., 2010). 
Among girls belonging to ethnic minority groups, ethnic differences played a very 
important role in awareness about HPV and other beliefs regarding immunization. Only 63% of 
the surveyed people had even heard about HPV and only 12% had been vaccinated against HPV. 
It was also seen that African Americans and Chinese participants were not very supportive of 
including the HPV vaccine in a school-based immunization program. A huge barrier for these 
people was lack of information about HPV and its associated risks. A few participants also had 
concerns that it would negatively damage their child’s health or lead to fertility problems in the 
future (Bastani et al., 2011). 
The prevalence of HPV vaccination among minority groups in the UK showed that the 
uptake of vaccination varied by ethnicity – the highest rates were observed among Asians, 
followed by White people and finally Black people. The rate of acceptability of the vaccine was 
76% among White people compared to 61% among non-White people. The lowest levels of 
acceptance (11-24%) were seen among South Asian parents. Religious beliefs about not having 
premarital sex also played a role in influencing parents’ decision regarding HPV vaccination 
(Marlow, 2011). 
Another study found differences in HPV vaccination status vary with ethnicity. This 
study showed that the chances of African American women going for vaccination were much 
lower than those of White women. Also, Asian women were less inclined towards HPV 
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vaccination compared to White women (Fisher, Trotter, Audrey, MacDonald-Wallis, & 
Hickman, 2013). 
Some healthcare providers feel reluctant to talk to ethnic minority groups about 
vaccination if they feel it would go against the patient’s culture. There is additional resistance 
due to the Tuskegee syphilis experiment in which African Americans in the USA were used for 
studying the progression of syphilis without their knowledge or consent. Hence, a number of 
minority groups mistrust the motives of healthcare professionals in recommending vaccination 
(Ferrer et al., 2014). 
Studies also show that women coming from low-family-income households are less 
likely to complete their HPV vaccination course. Also, women coming from deprived 
households were more often not HPV vaccinated (Fisher et al., 2013). 
Barriers are not seen only in the low-income groups or people who do not have access to 
information. A low level of compliance for HPV vaccination is also observed among people who 
have a high income and access to good educational facilities. These people have been observed 
to give little importance to the risk of acquiring HPV infection and hence they do not consider it 
necessary to go for vaccination (Hopenhayn, A. Christian, Christian, & Schoenberg, 2007; 
Woodhall et al., 2007). Some healthcare professionals in the US feel that HPV is not an infection 
that could be transmitted or prove dangerous in a school setting and hence believe it is not 
necessary to introduce HPV vaccination as part of school-based immunization programs. 
According to a pediatrician in US, “It would not be a school or a public-health issue, but more of 
an individual issue.” This further reduces the convictions of parents that HPV vaccination is 
necessary for their children (Ferrer et al., 2014). 
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Gender is another issue as most of the marketing strategies and informational campaigns 
have concentrated on women, making men feel unsure about the necessity of the vaccination. 
Most people feel that HPV infection is a “woman’s disease” and is not relevant to men, and so 
do not think about the vaccination for their adolescent male children (Daley et al., 2011). 
Healthcare providers have taken a number of measures to overcome these cultural 
barriers by bringing in more bilingual and bicultural staff, concentrating on recruitment of 
diverse staff, and reaching out to minority groups through their community organizations (Daley 
et al., 2011). 
Financial Barriers   
Gardasil, which is an HPV quadrivalent (types 6, 11, 16 and 18) recombinant vaccine, is 
the most expensive vaccine recommended for genital warts, being priced at $360 for the total 
regimen (Gudeman, 2007). Research shows that health insurance does not cover the entire cost 
of the vaccine (Hopenhayn et al., 2007). Hence, the financial constraint coupled with lack of 
information makes it difficult for people to make an informed decision. 
Although low-income women are more likely to develop cervical cancer, they are much 
less likely to complete the HPV vaccination course than high-income women (Vadaparampil et 
al., 2013). A study of low-income participants found that only 58% of them could afford the 
entire cost of the vaccine. Thus, most of the women would go for the first dose after an intense 
discussion with a practitioner or an informational session about HPV vaccination; however, the 
high cost of the vaccine slowly eats away the motivation to go for the second and third doses 
(Kahn et al., 2008). Another study found that cost was a huge barrier to vaccination. Participants 
in the 18-22 age group said they were unlikely to go for vaccination if they had to bear the costs. 
Most of them only got vaccinated because their parents paid for it (Mortensen, 2010).  
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The same trend was seen even in high-income countries like the US. Participants in U.S. 
said that the cost of HPV vaccination was $135 for each of the three injections and this was 
either partially covered or not covered by insurance (Ferrer et al., 2014). Another study found 
that about 24.4% of people considered insurance coverage and 14.6% considered cost to be a 
deciding factor in the decision to acquire vaccination against HPV (Zimet, Weiss, Rosenthal, 
Good, & Vichnin, 2010). 
The financial burden also falls on the healthcare providers in buying the vaccine because 
of the chance that patients might not buy the vaccines from them (Dempsey & Davis, 2006). In 
the US, healthcare providers face a huge financial burden in providing HPV vaccines to their 
patients in terms of money as well as time. According to a practitioner in the US, “There is no 
way vaccines are cost-effective for us. It costs the US an incredible amount of money in terms of 
time.” Other financial concerns include high costs of buying vaccines in bulk, lack of healthcare 
insurance, and insufficient reimbursement by the insurance companies (Ferrer et al., 2014). One 
study found that 36.5% of the physicians considered cost of stocking vaccines as a barrier, 47.4% 
considered inadequate reimbursement a barrier, and 40.2% considered lack of timely 
reimbursement a barrier in buying and recommending HPV vaccines (Malo et al., 2013). 
Practitioners in Sweden were reluctant to bring up the topic of HPV vaccination with 
their patients if they felt that the patients couldn’t afford it. They considered it an ethical issue 
and against their morals to put their patients in a position where they were forced to spend a large 
amount of their money on something their practitioner thought was important, but not 
immediately vital. This hugely deterred practitioners from talking about HPV infection and 
vaccination with their patients (Ferrer et al., 2014).  
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Most people are not ready to pay more than $100 for the HPV vaccine. About 70% of the 
participants reported cost to be a barrier for HPV vaccination (Daley et al., 2011). Another study 
found that about 41.3% of the participants were less likely to go for HPV vaccination due to the 
high costs (Patel et al., 2012). 
In the US, only 56% of the people who took the first dose of the HPV vaccine went on to 
complete the course. The reasons for not completing the series included lack of insurance and 
low family income. About 76.4% of the participants said that they wanted it at a lower cost or at 
no cost, compared to only 20% of the participants who were ready to pay the entire cost of the 
vaccination (Laz, Rahman, & Berenson, 2013).  
In India, Gardasil has been introduced at a cost of $171 for three injections and thus it 
remains largely out of reach of most middle- and low-income families. Countries such as India 
have considered the possibility of local production of the vaccines at reduced costs. However, 
issues such as patents and technology can become a hurdle for this kind of advancement 
(Padmanabhan, Amin, Sampat, Cook-Deegan, & Chandrasekhran, 2010). 
Many people in Hong Kong are deterred by the high cost of the vaccine. In Hong Kong, 
the vaccine costs between $321 and $514 US. The fact that the vaccine was not included in the 
government’s child vaccination scheme influenced people to think that it was an unnecessary 
expense. People in Hong Kong are of the mindset that the extremely important vaccines would 
be available free-of-cost (Siu, 2014). 
As most of the marketing efforts of pharmaceutical companies manufacturing HPV 
vaccines have been targeted to women, it is not surprising to note that a number of immunization 
programs are available only for girls. A very important reason for this gender difference is 
financial constraints. A study conducted by Pearson et al. in 2014 in the US found that including 
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adolescent boys in school-based immunization programs would be extremely cost-ineffective. 
This could only work if the costs of the vaccine and its administration were extremely low. An 
initiative by the Australian health authorities in 2013 made HPV vaccination free and available 
to boys, and this step has attracted a lot of criticism with regards to its cost-effectiveness 
(Pearson et al., 2014). 
In Florida, if more physicians participated in the Vaccines for Children (VFC) program, 
their financial burdens regarding HPV vaccination would be significantly reduced. A survey 
conducted in 2007 found that the amount of reimbursement received for the cost of a vaccine 
plays a very important role in recommending the vaccine to a patient, with inadequate 
reimbursement resulting in a 55% less likelihood of recommending the vaccine. The VFC 
program provides free-of-cost vaccines for children who are eligible for Medicaid, Native 
American or Alaskan, or uninsured. This program allows even private practitioners to administer 
the vaccine to their patients (Malo et al., 2013) 
Statistics show that about 80% of cervical cancer cases are reported from the poorer 
nations, and this is due to unavailability of vaccination due to financial constraints (Katz et al., 
2010). A number of countries have begun offering the HPV vaccination free-of-cost as part of 
school-based programs or other immunization programs. Australia was the first country to start a 
school-based vaccination program for children ages 12-13 years in 2007 (Ferrer et al., 2014). 
The Danish National Board of Health started a childhood-immunization program in 2009 for 12-
year-old girls, and a catch-up vaccination program in 2008 for girls ages 13-15. Women ages 16-
26 years had to pay 470 euros to get vaccinated (Mortensen, 2010). Similar programs have also 
been introduced in the US, the UK, Sweden, and Canada (Ferrer et al., 2014). 
  
42
Initiatives have also been taken by the World Health Organization (WHO) through its 
Cervical Cancer Prevention and Control Costing (C4P) tool that was developed to improve 
accessibility to the HPV vaccine in middle- and low-income countries. This tool has helped 
countries get financially prepared for expenses such as service delivery strategies, and large-
scale transportation of vaccines and health workers in establishing a nation-wide immunization 
program. This tool was developed in response to a request for assistance from the Ministry of 
Health and Social Welfare (MOHSW) in Tanzania for the estimation of the cost for the 
introduction of HPV vaccination in the country. This tool provides a country-specific report on 
the estimated costs of additional resources for the incorporation of HPV vaccine to existing 
immunization programs over a 5-year time period. Based on estimates obtained from this tool, 
1.6 million of the 2.4 million girls in Tanzania had received the complete series of HPV 
vaccination over a period of five years. This is similar to other initiatives such as Program for 
Appropriate Technology in Health (PATH) in India, Uganda, Peru, and Vietnam, and a program 
that the London School of Hygiene and Tropical Medicine (LSHTM) implemented in Mwanza 
province in Tanzania (Hutubessy et al., 2012).  
Compliance Barriers    
The highly recommended HPV vaccine, Gardasil, is a three-dose vaccine requiring the 
first, second, and third doses at zero, two, and six months, respectively (McIntosh, Sturpe, & 
Khanna, 2008). This often becomes a challenge for people with limited access to transportation 
and little ability to take time off work (Herzog, Huh, Downs, Smith, & Monk, 2008). In a study 
analyzing the attitudes of people living in Denmark towards HPV vaccination, one of the reasons 
that came up for not getting vaccinated was that it was “too inconvenient to have three injections 
within six months” (Mortensen, 2010). 
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The fact that the vaccine must be kept in cold storage and the number of doses required 
were a huge barrier to vaccination programs. According to one of the participants, “reducing 
doses and reducing our reliance on the cold chain, those are the general directions we would like 
to see it go.” The healthcare providers also seemed reluctant in transporting staff and vaccines 
every few days for vaccination programs. The problems they faced were insufficient human 
resources in terms of limited health workers and capacity of the staff. According to the providers, 
it often becomes a challenge to cover three doses for an entire population (Wigle, Coast, & 
Watson-Jones, 2013). Problems also arise at the physician’s end in terms of availability and 
scheduling a patient three times for HPV vaccination (McIntosh et al., 2008). 
Reaching eligible girls to deliver HPV vaccination is often quoted as a challenge by most 
healthcare providers. In the case of school-based vaccination programs, poor planning strategies, 
and proper documentation were major hurdles in achieving 100% vaccination rates. According to 
one of the people involved in a school-based vaccination program, “It is a big challenge to 
adequately and effectively document the accepted names and the numbers of girls who received 
dose one, who received dose two, and who received dose three.” A further challenge was to 
make sure that even those children who were absent on the day the program took place in the 
school get covered (Wigle et al., 2013). 
School-based vaccination programs do not work in countries where school enrollment 
and attendance are very low. In Uganda, although school-based vaccination programs were 
carried out in combination with existing child public health days, only 52.6% coverage was 
achieved. In Vietnam, community health-center-based immunization programs proved to work 
better than school-based immunization programs (Wigle et al., 2013). 
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A small percentage of the people faced problems in going to the health center for three 
injections, getting a leave of absence from work or school, and lack of adequate transportation 
facilities. Also, only 50% of the participants said that they had a place where they could go to get 
vaccinated (Daley et al., 2011). Another study found that women who are at high risk for 
cervical cancer do not have access to healthcare facilities mainly due to lack of transportation 
(Scarinci et al., 2010). 
A disturbing study in Somalia found that most of the patients who initiate HPV 
vaccination do not complete it. Also, those who do return for the second and third doses do not 
do so in the recommended time interval. The reasons for this have been postulated to be lack of 
access to the healthcare system and language barriers (Pruitt, Reese, Grossardt, Shire, & 
Creedon, 2013). 
Another study conducted in 2013 evaluated the accessibility of healthcare centers for 
children living in Los Angeles and if proximity to safety-net clinics had any influence on the 
decision to get vaccinated against HPV. This study was inspired by previous studies showing 
that lack of access to healthcare services can be an important factor in dissuading people from 
undergoing vaccination. The study found that about 90% of Latina girls had easy access to a 
healthcare center, compared to 68% of Chinese girls and 70% of Korean girls. Also, it would 
take three times longer to go to a healthcare center by public transportation than in a personal 
vehicle. Hence, not owning a vehicle and relying on public transport can work negatively in 
making a decision to get vaccinated against HPV (Tsui et al., 2013). About 58% of physicians in 
Hong Kong reported that it was very difficult to get the patients to visit the clinic for their second 
and third doses of HPV vaccination, and 51.8% of the physicians said that the patients 
considered it time-consuming to come for multiple doses (Wong et al., 2013). 
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Among the people of Appalachian Kentucky, lack of transportation and prioritizing work 
and school over health are major barriers to HPV vaccination. According to a participant, “Me 
and my fiancé, neither one have a driver’s license, so we don’t have a car… We’re dependent on 
my mother to take us [places].” Even people who had access to transportation facilities 
considered lack of transportation to be a major barrier. Many women tend to place other 
responsibilities like caring for a newborn child over HPV vaccination. Also, full-time work can 
take up a lot of time in a person’s life and can lead to neglect of one’s health – “I work six days a 
week… from 9 a.m. until 8 p.m. in the evening, so it’s hard to make time for HPV vaccination” 
(Mills, Head, & Vanderpool, 2013). 
A study conducted in 2011 examined the levels of adherence to the HPV vaccine dosing 
schedule. The study found that very few people stuck to the recommended time interval for the 
second or third doses; most of them were either early or late for their scheduled visits. The 
reasons for not completing the vaccination course were adverse events or side effects after the 
first dose of vaccine, and the influence of the attitudes and beliefs of general practitioners or 
family members. Other common factors included forgetting about the appointment for 
subsequent doses of vaccination, lack of insurance, and inability to take time off work or other 
responsibilities (Widdice, Bernstein, Leonard, Marsolo, & Kahn, 2011). 
Most practitioners did not find the time during a routine consultation to explain in detail 
about the risks of HPV infection and the availability of HPV vaccination to their patients. 
According to one general practitioner, “You know, we’re asked to promote diabetes management 
and we’re asked to promote smoking cessation and things like that so there’s so many other 
things that we’re trying to fit in.” As reported with other studies, practitioners found it difficult to 
encourage patients to complete the three-dose schedule of HPV vaccination. Patients often 
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simply forgot to return to the clinic for subsequent doses or didn’t have the time to do so (Mazza, 
Petrovic, Grech, & Harris, 2014). 
One surprising barrier that was found to affect a general practitioners willingness to talk 
about HPV vaccination with a patient was the practitioners’ physical work environment. This 
included issues such as vaccine availability in the clinic, established routines for vaccine 
administration, and availability of nurses for vaccine administration. If the vaccine was not 
available on site, it usually became difficult to encourage patients to purchase the vaccine and 
come back for another appointment to have it administered (Mazza et al., 2014). 
Among college students in Taiwan, situational influences could affect a person’s decision 
to go for HPV vaccination (Kuo, Yeh, Sheu, & Wang, 2014). Results from the National 
Immunization Survey-Teen conducted in 2009 showed that only 26.7% of the participants had 
completed the course of HPV vaccination. Initiatives have been taken to encourage vaccine-only 
visits among patients, along with reminders to visit the clinic for the second or third dose of 
vaccination (Sudenga, Royse, & Shrestha, 2011). 
Initiatives such as making the vaccine available at community locations such as Walmart 
and community colleges have been considered. A lot of people seemed supportive and thought 
that it could do away with barriers such as access to transportation and everyday responsibilities 
(Mills et al., 2013). In order to address the issue of patients not returning for subsequent doses of 
HPV vaccination, efforts to establish a recall system or contact patients via practice nurses are 
under way (Mazza et al., 2014). 
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Supports Related to HPV Vaccination   
The following supports are available for HPV vaccination in adolescent males. 
Financial Supports   
In accordance with the recommendations for HPV vaccination and faced with alarming 
rates of HPV infection and cervical cancer, many countries have taken steps to encourage people 
to go for HPV vaccination. The first step was taken by Australia, when it started offering a 
school-based vaccination program in 2007 for all girls age 12-13 years. This was soon followed 
by other countries including the UK, Sweden, and Canada. In the US, young women who are 
eligible for insurance through Medicaid, are uninsured, or underinsured can get vaccinated 
against HPV free-of-charge. However, school-based immunization programs are still in the 
discussion phase in the US as, according to Ferrer, “policy makers in the USA were not clear that 
a school-based mandate for the HPV vaccine was appropriate” (Ferrer et al., 2014). 
The cost of the vaccine not only affects the patient’s decision, but it also affects the 
physician’s decision to buy and recommend the vaccine. The Vaccines for Children (VFC) 
program has been developed to “remove cost as a barrier for the immunization of children.” This 
program is federally funded and it offers free vaccines for Medicaid-eligible children, Native 
American or Alaskan children, and uninsured or underinsured children. Vaccines are bought 
from the manufacturers at a very low cost and distributed among physicians free-of-charge to 
encourage them to vaccinate all their eligible patients (Malo et al., 2013). 
In Denmark, the quadrivalent vaccine is offered free-of-charge to 12-year-old girls, and 
to girls ages 13-15 under the catch-up immunization program. The Danish National Board of 
Health has also taken the initiative to inform all eligible girls by mail to encourage maximum 
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coverage of vaccination. This has ensured about 67-76% rates of vaccination among girls born 
from 1993 to 1995 (Mortensen, 2010). 
Provider Encouragement and Recommendations    
It has been shown that the success of HPV vaccine in controlling the incidence of 
cervical cancer in women largely depends upon the rate at which pediatricians recommend the 
vaccine to parents of their eligible patients. Overall, physicians’ attitudes towards the vaccine 
seem positive, and in a number of places they are found to actively recommend the vaccine to 
their patients (Krieger, Katz, Kam, & Roberto, 2012). 
There are three types of healthcare providers who routinely recommend the vaccine to 
patients aged 9 – 26 years;  pediatricians, family physicians, and obstetricians. Data obtained 
from this survey showed that 34.6% of physicians recommended the vaccine to early 
adolescents, 52.7% recommended to middle adolescents, and 50.2% recommended the vaccine 
to late adolescents. Also, according to this study, “Pediatricians were significantly more likely 
than family physicians and obstetricians to “always” recommend HPV vaccination for almost all 
female age groups” (Vadaparampil et al, 2011). 
It is well known that provider recommendation is a strong predictor of whether a parent 
decides to vaccinate a child against HPV. Studies show that 55% of parents who have received a 
physician’s recommendation vaccinate their sons against HPV, as compared to only 1% of 
parents who had their son vaccinated but had not received a physician’s recommendation. 
According to this study, “Physician recommendation and education about HPV vaccine for 
males may be key strategies for improving vaccination” (Reiter et al., 2013). According to 
another study, “Recommendation of HPV immunization by primary care physicians (PCPs) has 
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been recognized as one of the most influential factors in the individual’s willingness to receive 
the vaccine” (Wong et al., 2013). 
Support from EHRs and Health Information Systems    
The importance of health information systems in vaccination is the “timely availability of 
sound data.” These systems are responsible for the generation, analysis, and dissemination of 
such data to the concerned people for appropriate action. This data can also be used to influence 
research, policy making, and program generation. It uses data-generation methods such as 
household surveys, censuses, and administrative returns to identify the number of children who 
have not been vaccinated. This data is then analyzed for research purposes, to find out the 
prevalence of vaccination in a certain population and to identify trends and/or barriers. This 
information can then be used to improve the uptake of vaccines (AbouZahr & Boerma, 2005). 
In the US, technologies including text messaging, email, social media, and electronic 
health records are used improve immunization rates. Improvements in the field of Health 
Information Technology help in the identification of children who have not been vaccinated and 
alert their parents of their child’s immunization schedule. According to current data, “The Health 
Information Technology for Economic and Clinical Health (HITECH) Act, part of the American 
Reinvestment and Recovery Act of 2009, included monetary incentives tied to meaningful use of 
Electronic Health Records (EHRs)” (Stockwell & Fiks, 2013). 
A number of interventions have been put in place to aid immunization uptake by the 
target population. One of the interventions involves electronic health record-derived 
immunization prompts that alert the physician when an unimmunized patient visits the clinic. 
Another intervention involves sending quarterly reports to the physician regarding the 
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immunization status of his/her patients, enabling the physician to send reminders to the 
unimmunized patients (Bundy et al., 2013). 
Support from Healthcare Information Security and Privacy    
Using electronic means to document patient data requires the collection of extensive 
personal and health-related patient information. This kind of data collection and storage can 
compromise privacy and can be used against him/her in insurance, employment, and government 
programs. For these reasons, the Model State Public Health Privacy Act provides guidelines to 
protect public health data, at the same time allowing state and local public health departments to 
use the data for the common good (Gostin, Hodge, & Valdiserri, 2001). 
In particular, the American Recovery and Reinvestment Act (ARRA) of 2009 
significantly focused on the issues of security and privacy of healthcare information. Before the 
enactment of the ARRA, the topic of information privacy had been stressed by the U.S. 
Government Accountability Office (GAO) and its efforts have led to stricter guidelines. This Act 
has increased the control an individual has over his/her health information and the individual can 
also restrict disclosure of this information. It also requires the signing of business associate 
contracts if the health information of a person needs to be shared with business associates for 
research purposes (Goldstein, 2010). 
The fear of breach of privacy resides not only with the patients, but also with the 
provider. Providers are often wary of revealing their patients’ data to third parties for fear of 
misuse of the information. According to a study, “Providers under-report notifiable disease cases 
to public health agencies.” These concerns have been taken care of by the Canadian jurisdiction 
and the U.S. Health Insurance Portability and Accountability Act (HIPAA) Privacy rule (Emam 
et al., 2011). 
  
51
Support from Regulatory Environment   
Legislative action has worked positively towards increasing awareness about HPV 
vaccination among parents and the general public. In a study, about 63.5% of the women said 
that they were more inclined to follow a law that made HPV vaccination mandatory for children. 
According to the study, “A majority expressed a high intent to comply with a hypothetical law 
mandating adolescent HPV vaccination for school attendance” (Carlos et al., 2011). 
In the US, the Centers for Disease Control and Prevention (CDC) and the World Health 
Organization (WHO) have published safety reports on the HPV vaccine. The CDC has also 
conducted post-licensing studies to assess the safety of the quadrivalent vaccine, Gardasil 
(Fernandez et al., 2012). With the involvement of the Advisory Committee on Immunization 
Practices (ACIP) of the CDC in recommending vaccination for girls ages 11-12 and catch-up 
vaccination for girls ages 13-26, a number of bills have been passed making the HPV vaccine 
mandatory for school children (Mello, Abiola, & Colgrove, 2012). 
A national, non-profit organization called Women in Government (WIG) has been 
involved in the legislation pertaining to HPV vaccination. Upon receiving educational grants 
from Merck, WIG conducted a number of educational conferences attracting a number of 
legislators involved in the work relating to HPV vaccination. According to one remark, “WIG bit 
off hook, line, and sinker the need to have mandated this vaccination across America” (Mello et 
al., 2012). 
In Europe, the European Medicines Agency (EMA) has allowed for the use of the 
quadrivalent vaccine in females up to 46 years old and in males up to age 26. This 
recommendation is the “basis for vaccine approval for males and male vaccination 
recommendations by EMA (Crosignani et al., 2013). 
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Support from State Policies   
State policies and other regulatory activities have been highly instrumental in improving 
the uptake of the HPV vaccine. The efforts usually deal with financing HPV vaccination through 
the Vaccines for Children (VFC) program, Medicaid and private insurance, laws relating to 
mandatory HPV vaccination, and educational campaigns about HPV vaccination. According to a 
study, “To increase coverage, many states have introduced legislation to require private 
insurance companies to cover the HPV vaccine.” Some states have also supplemented federal 
funds and started providing the vaccine at very little or no cost. Another policy to increase 
uptake of the vaccine is to introduce mandates for school children and immigrants. Some states 
have also made it compulsory that information about HPV vaccines should be included as part of 
the curriculum of sex education in schools (Fernandez et al., 2010). 
Policies with respect to vaccination usually focus on the target age group for the 
particular vaccine, the age group that can be considered for a catch-up program, revisions of 
screening policies with respect to HPV DNA testing, and inclusion of boys for HPV vaccination 
programs (Kim, Brisson, Edmunds, & Goldie, 2008). “Cost-effectiveness evaluations are 
designed to assist in population-level decision-making at a government or policy-maker 
perspective” (Canfell et al., 2012). 
Some states have also incorporated default policies to allow individuals to opt-in or opt-
out of health services. Such policies have had a very positive effect on influenza vaccination and 
organ donation in the past. According to a study, default policies were found to make the parents 
more likely to get their children vaccinated against HPV (Reiter et al., 2012).  
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Support from the U.S. National Vaccine Plan  
The U.S. National Vaccine Plan was implemented with the aim of achieving five goals – 
to develop new and better vaccines, to improve the safety profiles of the existing vaccines, to 
improve decision-making to enhance vaccines, to provide access to all vaccines within the US, 
and to help combat global diseases better through vaccination. The National Vaccine Plan 
implemented in 2010 aimed to build a stronger health system by improving the uptake of 
preventative vaccines. In following the guidelines of the National Vaccine Plan, a child can be 
protected against 17 diseases through vaccination, and a number of financial barriers that earlier 
restricted the uptake of vaccines, have now been removed (US Department of Health and Human 
Services, 2010). 
The priorities in the National Vaccine Plan implementation guidelines include developing 
a list of all important vaccines, enabling easier development and licensing of new vaccines, 
encouraging studies on vaccine safety, improving awareness of important vaccines among the 
public, working on removing financial barriers for the physicians and the public, encouraging the 
use of health information technology and electronic health records (EHRs), and encouraging the 
global introduction of important vaccines to help eradicate diseases (US Department of Health 
and Human Services, 2010). 
As of 2014, leaders involved in decisions regarding implementation of the National 
Vaccine Plan are looking for areas that need intervention in the current context. Some of the 
priorities include improving communication with the providers, improving access to health 
insurance and other measures taken to protect public health, improving the rates of adult 
immunization, and in improving coverage of HPV vaccination among adolescents. 
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Future Directions for Research  
This literature review has thrown light upon the various barriers and the supports that 
exist for healthcare professionals in recommending HPV vaccination. There are many classes of 
hindrances and supports that exist for healthcare workers, parents, and young men in terms of 
knowledge, safety and efficacy, financial matters, cultural issues, and psychological barriers. 
Very little is known about the prevalence of physician recommendations and organizational 
encouragements. 
Future research in this field needs to focus on capturing better data concerning unhealthy 
behaviors among people. Major challenges include small sample sizes, low response rates, 
convenience samples, lack of appropriate evidence-based theories, and hypothetical story lines. 
Hence, it is important to analyze the healthcare professionals’ current outlook on HPV 
vaccination, the uptake of these vaccines by male adolescents, and the introduction of new state 
policies concerning HPV vaccine for increasing knowledge in this domain. It is also important to 
determine the actual behaviors of the healthcare professionals involved with respect to HPV 
vaccination, especially for pre-adolescent and adolescent males.  
Future research should also focus on the attitudes of the adolescents as well as their 
parents concerning HPV vaccination. In order to decrease the prevalence of HPV, adolescents 
will need motivation from parents or other role models to change their attitude towards 
vaccination.   
Conclusions on Literature Review   
This literature review has summarized commonly identified barriers people might face in 
getting themselves or their children vaccinated against HPV, and barriers that might prevent 
primary healthcare providers from recommending the vaccine to their patients. As expected, the 
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barriers vary with geographical location, ethnicity, gender, age group, financial status, societal 
influences, religious beliefs, and family or peer pressure.  
The governments of various countries have not been blind to these barriers, and a number 
of steps have been taken to make it easier for healthcare providers and patients to decide to 
acquire vaccination against HPV. For example, the National Vaccine Plan was developed in 
1994 to spread awareness about the benefits of acquiring vaccines. With assistance from the 
National Institute of Health (NIH), more than 20 new vaccines have gained approval from the 
Food and Drug Administration (FDA). These include vaccines against pediatric pneumococcal 
disease, meningococcal disease, and HPV (Teitelbaum & Wilensky, 2012). 
Vaccines for Children (VFC) is a federally funded program that has been implemented to 
provide essential vaccines for free to children (Katz et al., 2009). The CDC and the WHO Global 
Advisory Committee on Vaccine Safety have taken a number of measures to assess the safety of 
the HPV vaccines. The CDC has also conducted post-licensing studies to evaluate the safety of 
the quadrivalent vaccine, Gardasil (Fernandez et al., 2010). Other organizations that work hard to 
ensure maximum coverage of important vaccines include the Institute of Medicine (IOM), the 
U.S. Advisory Committee on Immunization Practices, the Department of Health and Human 
Services (HHS), the National Vaccine Program Office (NVPO), and the Health Resources and 
Services Administration (Chesson, Bladford, Gift, Tao, & Irwin, 2008; Thaul, 2005). 
Thus, although barriers are many, efforts to overcome them are constantly being initiated 
and modified to ensure optimum health for all citizens. The US health departments in particular 
have taken many initiatives such as publicly available insurance policies and school-based 
immunization programs to provide the maximum protection against infectious diseases at the 
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least inconvenience to the public. It is highly plausible that the listed barriers against HPV 
vaccination will soon be overcome in the ongoing effort to create healthy lives and environment. 
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CHAPTER 3   
RESEARCH METHODS 
Nature of Research Study   
The study design for this research is cross-sectional and observational, based on 
secondary source of data. 
Data   
Clinical specialty data for HPV vaccine recommendation among adolescent males were 
drawn from the 2014 profile of rural healthcare providers of all 10 affiliates of Albany Area 
Primary Health Care, Inc..  Albany Area Primary Health Care, Inc. is an affiliate of the Georgia 
Association for Primary Health Care (GAPHC) and also a Federally Qualified Health Center 
(FQHC). It is located in Albany, GA, and provides healthcare services to rural and underserved 
communities in southwest GA.  Questions on perceived barriers and rates of HPV vaccination 
recommendations were administered as a paper-based survey instrument to a representative 
sample of 70 clinical specialists (family practice, pediatricians, and nurse practitioners) and 
completed by 51 healthcare providers.  The response rate for the healthcare providers was 76%.  
Albany Area Primary Health Care adopted a previously validated survey tool developed 
by researchers from the Moffitt Cancer Center and tested by Susan Vadaparampil (2009) from a 
nationwide survey. The research study conducted by Susan Vadaparampil was on HPV 
intervention.  The researchers validated the instrument through two rounds of expert panel 
review with HPV researchers and clinicians, as well as through interviews with physicians (n = 
7) and a pilot study with randomly selected physicians (n = 16) with expertise in this field 
(Vadaparampil et al., 2011).  
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The purpose of this study was to examine the healthcare provider’s inclinations regarding 
recommendation of HPV vaccine for male adolescents, especially those ages 11–12, 13–17, and 
18–26. The secondary data was drawn from data provided to the researcher that was obtained 
through a survey taken by a sample of medical practitioners based on their experiences in dealing 
with the target sample of male patients between the ages of 11 and 26 years old. Based on the 
responses obtained from this target sample of healthcare providers in the Albany Area Primary 
Care, inferences will be made on the entire population of patients in these age groups.  The 
Institutional Review Board of Georgia Southern University approved exemption status for this 
research. 
Variables   
The research study used variables such as age of male patients, clinical specialties of the 
respondent health workers, frequency of recommendation for vaccine uptake, frequency of 
vaccine administration, parent’s fears and concerns on the effects of the vaccine being 
administered.  Paired t tests and analysis of variance (ANOVA) were used to determine the 
relationships between provider recommendations to patients and vaccine uptake completion. The 
primary variables in this research study were the specialty of practice, age of target patients, 
gender of the practitioners, and race. These variables were analyzed against each other with the 
independent variable being age, gender, and specialty of medical practice. The main dependent 
variables were the frequency with which health providers to recommend the HPV vaccine as 
well as the frequency of administration of this vaccine to the target population of male patients in 
the chosen age groups.      
General Demographics of the Target Population  
In accordance to Federal Regulations Title 45 Part 46, this research study was determined 
not to require full review and was exempted by the Georgia Southern University Institutional 
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Review Board (GSU-IRB).  This was due to the fact that the study involved the use of publicly 
available data as well as participants who cannot be identified.  Upon subsequent approval by the 
GSU-IRB, the publicly available secondary data (N = 51) was obtained from Albany Area 
Primary Health Care (AAPC), Incorporated. AAPC is a FQHC, headquartered in Albany, 
Georgia and has clinics in several surrounding rural counties in southwest Georgia providing 
care to 35,000 diverse individuals and seeing 120,000 patient visits per annum. The facilities 
deliver services to children and adults through primary healthcare providers such as family 
physicians, pediatricians, and nurse practitioners. According AAPC, out of this population, data 
was randomly collected pertaining to adolescents in the age groups of 11-12 years, 13-17 years, 
and 17 – 26 years. A total representative sample of 15 family practitioners, 17 nurses, and 19 
pediatricians were used in this study to collect data on the frequency of HPV vaccine 
recommendation to their patients in the varying age categories. 
Statistical Analysis   
Paired t tests and ANOVA were carried out in investigating the statistical differences that 
exist between the clinical specialties. The research revolves around the recommendation of the 
HPV vaccine among the various age groups, which in effect means that the primary response in 
this analysis was health provider recommendations of HPV vaccination. The dependent variables 
obtained in this research study were based on the Likert-type scale, offered in the questionnaires 
administered to the various health providers. An assumption was made that responses by the 
health sector service providers in the sample were representative of the general approach by each 
of the medical practitioners in dealing with all his/her clients in as far as recommending the HPV 
vaccine. This recoding was selected as most appropriate as it reflects best practices employed by 
health providers in recommending the vaccine. 
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CHAPTER 4   
RESULTS 
This section presents the results of our analyses in responses to the questions listed in 
Chapter 1. All analyses were performed in SPSS, version 23. This study explored providers’ 
tendency to recommend HPV vaccine to early male adolescents (age 11–12); as evidence 
indicates that this is the most preferred age to introduce the HPV vaccine to ensure long-term 
effectiveness.  The frequencies and percentages for the healthcare providers’ demographic 
characteristics can be found in Table 1. There were 54 healthcare providers that data was 
gathered from in the study.  The majority were nurses (N = 33, 64.7%) followed by family 
medicine workers (N = 12, 23.5%) and the smallest group was pediatrics (N = 6, 11.8%). Three 
of the providers did not indicate their field of specialty.  
Provider age varied.  The majority were 24-32 years of age (N = 22, 41.5%). Next in 
respective order were 42-50 years of age (N = 14, 26.4%), 33-41 years of age (N = 12, 22.6%) 
and 51 years of age or older (N = 5, 9.4%).  One provider did not indicate their age.   
Gender representation was not balanced among providers. The majority were female (N 
= 44, 84.6%) and the rest male (N = 8, 15.4%).  Two providers did not indicate their gender. 
Race was varied among providers with white being the majority (N = 29, 55.8%) of this sample.  
Respectively followed by black (N = 18, 34.6%), prefer not to answer (N = 2, 3.8%), Asian (N = 
1, 1.9%), native Hawaiian/pacific islander (N = 1, 1.9%), and mixed race (N = 1, 1.9%).  Two 
providers did not identify and racial category. 
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Table 1 
Frequencies and Percentages for Healthcare Providers’ Background Characteristics  
Provider Characteristic Frequency Percent 
Type of Healthcare Provider   
Pediatrics 6 11.8 
Family Medicine 12 23.5 
Nurses 33 64.7 
Total 51 100.0 
Provider Age   
24 - 32 years 22 41.5 
33 - 41 years 12 22.6 
42 - 50 years 14 26.4 
51+ 5 9.4 
Total 53 100.0 
Provider Gender   
Male 8 15.4 
Female 44 84.6 
Total 52 100.0 
Provider Race   
White / Caucasian 29 55.8 
Asian 1 1.9 
Native Hawaiian / Pacific Islander 1 1.9 
Black / Black American 18 34.6 
Mixed race 1 1.9 
Prefer not to answer 2 3.8 
Total 52 100.0 
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Research Question A  
Research Question A was, are healthcare providers' rates of recommending HPV 
vaccination for males aged 11 to 12 years old higher than those of males aged 13 to 17 years old? 
Null Hypothesis: No difference exists between healthcare providers’ prevalence of 
recommending HPV vaccines to either early (ages 11-12) adolescent or middle (ages 13-
17) adolescent males. 
Alternate Hypothesis: A difference exists between the healthcare providers’ prevalence of 
recommending HPV vaccines to early (ages 11-12) adolescent and middle (ages 13-17) 
adolescent males. 
A paired samples t test was used to address the hypotheses. The null hypothesis was retained 
(t(46) =-1.771, p = .083).  There was no significant difference found between healthcare 
providers’ prevalence of recommending HPV vaccines to either early (ages 11-12) adolescents 
(M = 2.51, SD = 1.988) or middle (ages 13-17) adolescent males (M = 2.64, SD = 1.983). See 
Table 2. 
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Table 2 
Paired Samples T Test for Recommending HPV Vaccines to Either Early (Ages 11-12) 
Adolescent or Middle (Aged 13-17) Adolescent Males 
 Paired Differences 
t df Sig. 
Mean Std. 
Deviation 
SE 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 recommend 
vaccine to 11-
12yrs versus 
13-17yrs 
-.128 .494 .072 -.273 .017 -1.771 46 .083 
 
Research Question B  
Research Question B was, are healthcare providers' rates of recommending HPV 
vaccination for middle adolescent males (ages 13-17) higher than those of late adolescent (ages 
18-26 years) males? 
Null Hypothesis: No difference exists between healthcare providers’ prevalence of 
recommending HPV vaccines to either middle adolescent or late adolescent males. 
Alternate Hypothesis: Differences exist between healthcare providers’ prevalence of 
recommending HPV vaccines to middle adolescent and late adolescent males. 
A paired samples t test was used to address the hypotheses. The null hypothesis was retained 
(t(46) =1.499, p = .141).  There was no significant difference found exists between healthcare 
providers’ prevalence of recommending HPV vaccines to either middle adolescents (M  = 2.64, 
SD = 1.983)  or late adolescent males adolescents (M = 2.45, SD = 1.851). See Table 3. 
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Table 3 
Paired Samples T Test for Recommending HPV Vaccines to Either Middle Adolescent or Late 
Adolescent Males 
 Paired Differences 
t df Sig. 
Mean 
Std. 
Deviation 
SE 
Mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
 recommend 
vaccine to 13-
17yrs versus 
18-26yrs 
.191 .876 .128 -.066 .449 1.499 46 .141 
 
Research Question C     
Research Question C was, are healthcare providers' rates of recommending HPV 
vaccination for late adolescent males (aged 11-12) higher than those of early adolescent males 
(aged 18-26)?  
Null Hypothesis: No difference exists between healthcare providers’ prevalence of 
recommending HPV vaccines to either late adolescent (aged 11 -12) or early male 
adolescent males (aged 18-26). 
Alternate Hypothesis: Differences exist between healthcare providers’ prevalence of 
recommending HPV vaccines to late adolescence (aged 11-12) and early adolescence 
males (aged 18-26). 
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A paired samples t test was used to address the hypotheses. The null hypothesis was retained 
(t(46) =.443, p = .660).  There was no significant difference found between healthcare providers’ 
prevalence of recommending HPV vaccines to adolescent (M = 2.45, SD = 1.851) late 
adolescence (aged 13-17) and adolescent (M =  2.64, SD = 1.983) early adolescence males (aged 
18-26). See Table 4. 
Table 4 
Paired Samples Test for Healthcare Providers’ Prevalence of Recommending HPV Vaccines to 
Late Adolescence (Ages 11-12) and Early Adolescence Males (Ages 18-26) 
 Paired Differences 
t df Sig. 
Mean 
Std. 
Deviation 
SE 
Mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
 recommend 
vaccine to 11-
12yrs - versus 
18-26yrs 
.064 .987 .144 -.226 .354 .443 46 .660 
 
 
Research Question D    
Research Question D was, is there a variation in rates at which specialist healthcare 
providers’ (FPs, NPs, Peds) recommend HPV vaccines? 
Null Hypothesis: No difference exists between specialist healthcare providers in their 
prevalence of recommending HPV vaccines to patients. 
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Alternate Hypothesis: Differences exist between specialist healthcare providers in their 
prevalence of recommending HPV vaccines to patients. 
ANOVA was used to address the hypotheses. The null hypothesis was retained for patients 11-12 
years old (F(2,44) = 1.456, p = .244), as there were no difference in pediatric, family medicine, 
and nurse healthcare providers’ prevalence of recommending HPV vaccines to patients in this 
age group. The null hypothesis was retained for patients 13-17 years old (F(2,43) = 2.328, p = 
.110) as there were no difference in pediatric, family medicine, and nurse healthcare providers’ 
prevalence of recommending HPV vaccines to patients in this age group. Finally, null hypothesis 
was retained for patients 18-26 years old (F(2,43) = 1.511, p = .232) as there were no difference 
in pediatric, family medicine, and nurse healthcare providers’ prevalence of recommending HPV 
vaccines to patients in this age group. There are no difference exists between specialist 
healthcare providers in their prevalence of recommending HPV vaccines to patients (see Table 5 
and 6). 
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Table 5 
Group Means for Healthcare Provider Recommendation Rates 
Type of Healthcare Provider recommend 
vaccine to 11-
12yrs 
recommend 
vaccine to 13-
17yrs 
recommend 
vaccine to 18-
26yrs 
Pediatrics M 1.50 1.67 1.50 
N 6 6 6 
SD 0.837 0.816 0.837 
Family medicine M 3.08 3.50 3.00 
N 12 12 12 
SD 1.730 1.567 1.537 
Nurses M 2.34 2.36 2.29 
N 29 28 28 
SD 2.092 2.129 1.979 
Total M 2.43 2.57 2.37 
N 47 46 46 
SD 1.920 1.940 1.793 
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Table 6 
ANOVAs for Specialist Healthcare Providers in Their Prevalence of Recommending HPV 
Vaccines to Patients 
Age Group Sum of 
Squares 
df Mean 
Square 
F Sig. 
recommend vaccine 
to 11-12yrs 
Between 
Groups 
10.521 2 5.260 1.456 .244 
Within Groups 158.968 44 3.613   
Total 169.489 46    
recommend vaccine 
to 13-17yrs 
Between 
Groups 
16.542 2 8.271 2.328 .110 
Within Groups 152.762 43 3.553   
Total 169.304 45    
recommend vaccine 
to 18-26yrs 
Between 
Groups 
9.503 2 4.752 1.511 .232 
Within Groups 135.214 43 3.145   
Total 144.717 45    
 
Research Question E   
Research Question E was, are healthcare providers' encountering perceived barriers in 
recommending HPV vaccine to adolescent males?  
Null Hypothesis: No perceived barriers exist among healthcare providers’ prevalence of 
recommending HPV vaccines to adolescents males. 
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Alternate Hypothesis: Perceived barriers exist among healthcare providers’ prevalence of 
recommending HPV vaccines to adolescents males. 
Frequencies and percentages were used to address the hypotheses. The null hypothesis is rejected 
because perceived barriers were reported among healthcare providers’ prevalence of 
recommending HPV vaccines to adolescents males in discussing sexuality, vaccinating teens 
with riskier sexual behavior, adding another vaccine to the vaccine schedule, and when 
vaccination is not required for school attendance (see Table 7). 
 Providers were asked five questions about perceived barriers were reported among 
healthcare providers’ prevalence of recommending HPV vaccines to adolescents males.  In the 
first question, discussing sexuality, the majority answered (N = 17, 32.1%), followed by strongly 
agree (N = 16, 30.2%), strongly disagree (N = 11, 20.8%), somewhat disagree (N = 11, 20.8%), 
and neutral (N = 3, 5.7%).  The second question was about vaccinating teens with riskier sexual 
behavior.  The majority answered strongly agree (N = 21, 40.4%), somewhat agree (N = 13, 
25.0%), somewhat disagree (N = 9, 17.3%), strongly disagree (N = 5, 9.6%), and neutral (N = 4, 
7.7%). The third question was adding another vaccine to vaccine schedule.  The majority 
answered somewhat disagree (N = 15, 28.3%) followed by neutral (N = 13, 24.5%), somewhat 
agree (N = 13, 24.5%), strongly disagree (N = 8, 15.1%), and strongly agree (N = 4, 7.5%).  The 
fourth question asked do you take time to discuss HPV with patients/parents. The majority 
answered both somewhat disagree (N = 14, 26.4%) and somewhat agree (N = 14, 26.4%) 
followed by neutral (N = 12, 22.6%), strongly disagree (N = 7, 13.2%), and strongly agree (N = 
6, 11.3%). The final question asked should vaccination not required for school attendance. The 
majority answered somewhat agree (N = 14, 26.4%), followed by somewhat disagree (N = 12, 
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22.6%), neutral (N = 12, 22.6%), strongly disagree (N = 10, 18.9%), and strongly agree (N = 5, 
9.4%). 
Table 7 
Frequency and Percentages for Healthcare Providers' Encountering Perceived Barriers in 
Recommending HPV Vaccine to Adolescent Males 
Barriers Frequency Percent 
Discussing Sexuality   
Strongly disagree 11 20.8 
Somewhat disagree 6 11.3 
Neutral 3 5.7 
Somewhat agree 17 32.1 
Strongly agree 16 30.2 
Total 53 100.0 
Riskier Sexual Behavior   
Strongly disagree 5 9.6 
Somewhat disagree 9 17.3 
Neutral 4 7.7 
Somewhat agree 13 25.0 
Strongly agree 21 40.4 
Total 52 100.0 
Adding Another Vaccine to Vaccine Schedule   
Strongly disagree 8 15.1 
Somewhat disagree 15 28.3 
Neutral 13 24.5 
Somewhat agree 13 24.5 
Strongly agree 4 7.5 
Total 53 100.0 
Takes Time to Discuss HPV with Patients/Parents   
Strongly disagree 7 13.2 
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Somewhat disagree 14 26.4 
Neutral 12 22.6 
Somewhat agree 14 26.4 
Strongly agree 6 11.3 
Total 53 100.0 
Vaccination is not Required for School Attendance   
Strongly disagree 10 18.9 
Somewhat disagree 12 22.6 
Neutral 12 22.6 
Somewhat agree 14 26.4 
Strongly agree 5 9.4 
Total 53 100.0 
 
Research Question F   
Research Question F was, is there variation in recommending rates by demographic 
characteristics of the provider?  
Null Hypothesis: There is no variation in recommending rates by demographic 
characteristics of the provider. 
Alternate Hypothesis: There is variation in recommending rates by demographic 
characteristics of the provider. 
ANOVAs were used to address the hypothesis.  
Provider age.  The first set of ANOVAs were used to examine average differences in 
referral rates by provider age. The null hypothesis was retained for patients 11-12 years old 
(F(3,43) = 2.319, p = .088), 13-17 years old (F(3,43) = 2.252, p = .096), and 18-26 years old 
(F(3,43) = 2.195, p = .102) when the independent variable was provider age (see Tables 8 & 9). 
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Table 8 
Recommendation Rates by Age of Provider and Age of Vaccination Recipient 
Provider age recommend 
vaccine to 11-
12yrs 
recommend 
vaccine to 13-
17yrs 
recommend 
vaccine to 18-
26yrs 
24 - 32 years M 2.21 2.42 2.32 
N 19 19 19 
SD 1.843 1.895 1.797 
33 - 41 years M 3.58 3.67 3.42 
N 12 12 12 
SD 2.021 1.969 2.065 
42 - 50 years M 2.38 2.50 2.17 
N 13 12 12 
SD 2.063 2.111 1.697 
51+ M 1.00 1.00 1.00 
N 4 4 4 
SD .000 .000 .000 
Total M 2.50 2.64 2.45 
N 48 47 47 
SD 1.968 1.983 1.851 
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Table 9 
ANOVAs for Age of Provider and Age of Vaccination Recipient 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
recommend 
vaccine to 11-12yrs 
Between 
Groups 
24.849 3 8.283 2.319 .088 
Within 
Groups 
157.151 44 3.572   
Total 182.000 47    
recommend 
vaccine to 13-17yrs 
Between 
Groups 
24.553 3 8.184 2.252 .096 
Within 
Groups 
156.298 43 3.635   
Total 180.851 46    
recommend 
vaccine to 18-26yrs 
Between 
Groups 
20.928 3 6.976 2.195 .102 
Within 
Groups 
136.689 43 3.179   
Total 157.617 46    
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 Provider race. The next set of ANOVAs were used to examine average differences in 
referral rates by provider race. The null hypothesis was retained for patients 11-12 years old 
(F(5,41) = 1.398, p = .245), 13-17 years old (F(5,40) = 1.345, p = .226), and 18-26 years old 
(F(5,40) = 1.586, p = .186) when the independent variable was provider race (see Tables 10 & 
11). 
Table 10 
Recommendation Rates by Provider Race and Age of Vaccination Recipient 
Provider race/ethnicity recommend 
vaccine to 
11-12yrs 
recommend 
vaccine to 13-
17yrs 
recommend 
vaccine to 
18-26yrs 
White / Caucasian M 2.24 2.32 2.16 
N 25 25 25 
SD 1.964 1.952 1.930 
Asian M 5.00 5.00 5.00 
N 1 1 1 
SD . . . 
Native Hawaiian / Pacific Islander M 1.00 1.00 4.00 
N 1 1 1 
SD . . . 
Black / Black American M 2.82 2.88 2.41 
N 17 17 17 
SD 1.944 1.965 1.583 
Mixed race M 6.00 6.00 6.00 
N 1 1 1 
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SD . . . 
Prefer not to answer M 1.50 1.00 1.00 
N 2 1 1 
SD .707 . . 
Total M 2.53 2.61 2.41 
N 47 46 46 
SD 1.977 1.994 1.857 
 
Table 11 
ANOVAs for Race of Provider and Age of Vaccination Recipient 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
recommend vaccine to 11-
12yrs 
Between 
Groups 
26.172 5 5.234 1.398 .245 
Within Groups 153.531 41 3.745   
Total 179.702 46  
 
  
recommend vaccine to 13-
17yrs 
Between 
Groups 
25.752 5 5.150 1.345 .266 
Within Groups 153.205 40 3.830   
Total 178.957 45  
 
  
recommend vaccine to 18-
26yrs 
Between 
Groups 
25.675 5 5.135 1.586 .186 
Within Groups 129.478 40 3.237   
Total 155.152 45    
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Provider gender. The next set of ANOVAs were used to examine differences in referral 
rates by provider gender. The null hypothesis was retained for patients 11-12 years old (F(1,45) 
= 0.022, p = .883), 13-17 years old (F(1,44) = 0.218, p = .643), and 18-26 years old (F(1,44) = 
0.020, p = .887) when the independent variable was provider gender (see Tables 12 & 13). 
Table 12 
Referral Rates by Gender of Provider and Age of Vaccination Recipient 
Provide gender  recommend 
vaccine to 11-
12yrs 
recommend 
vaccine to 13-
17yrs 
recommend 
vaccine to 18-
26yrs 
Male M 2.43 3.00 2.57 
N 7 7 7 
SD 1.618 1.633 1.397 
Female M 2.55 2.62 2.46 
N 40 39 39 
SD 2.050 2.060 1.945 
Total M 2.53 2.67 2.48 
N 47 46 46 
SD 1.977 1.989 1.859 
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Table 13 
ANOVAs for Gender of Provider and Age of Vaccination Recipient 
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
recommend vaccine to 
11-12yrs 
Between 
Groups 
.088 1 0.088 0.022 .883 
Within Groups 179.614 45 3.991   
Total 179.702 46    
recommend vaccine to 
13-17yrs 
Between 
Groups 
.878 1 0.878 0.218 .643 
Within Groups 177.231 44 4.028   
Total 178.109 45    
recommend vaccine to 
18-26yrs 
Between 
Groups 
.072 1 0.072 0.020 .887 
Within Groups 155.407 44 3.532   
Total 155.478 45    
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Summary  
 Data were gathered from 54 healthcare providers.  The majority were nurses followed by 
family medicine workers, and providers in pediatrics. Provider age varied, but was on the young 
side since these were students.  The majority of providers were also White and female. 
The null hypothesis was retained on four of five research questions. For the Research 
Question A, there were no statistically significant differences between healthcare providers’ 
prevalence of recommending HPV vaccines to either early (ages 11-12) adolescent or middle 
(ages 13-17) adolescent males.  For Research Question B, there were no statistically significant 
differences between healthcare providers’ prevalence of recommending HPV vaccines to either 
middle adolescent or late adolescent males. For Research Question C, there were no statistically 
significant differences between healthcare providers’ prevalence of recommending HPV 
vaccines to either late adolescent (ages 11 -12) or early male adolescent males (ages 18-26).   
For Research Question D, there were no statistically significant differences in rates at 
which specialist healthcare providers recommended HPV vaccines. The null hypothesis was 
rejected for Research Question E. Perceived barriers were reported among healthcare providers’ 
prevalence of recommending HPV vaccines to adolescents males in discussing sexuality, 
vaccinating teens with riskier sexual behavior, adding another vaccine to vaccine schedule, and 
when vaccination is not required for school attendance. For Research Question F, there were no 
statistically significant differences in recommending rates by demographic characteristics of the 
provider. 
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CHAPTER 5    
SUMMARY DISCUSSION AND CONCLUSIONS   
Discussion  
While the CDC clearly recommends the HPV vaccine for boys and girls ages 11-12, the 
results here and in the literature review show a marked preference by FPs, NPs, Peds, and 
parents to vaccinate at a later age. There is some uneasiness among healthcare providers and 
parents regarding the vaccination of pre-teens when it concerns a sexually transmitted disease. 
Perhaps by educating healthcare providers on how to address these concerns with parents, the 
rate of HPV vaccination among the younger population will improve. It is also important to 
increase the awareness of healthcare providers and parents to the role that males play in the 
spread of HPV so that more of them are vaccinated. While it is true that HPV vaccines at first 
were only recommended for females, the CDC’s current recommendation is that all children 
should be vaccinated by 11 or 12. 
The HPV vaccine is currently not required by many state governments, including that of 
Georgia. This determination is made by the states themselves and some considerations that are 
taken into account are support by the community, monetary requirements for implementation, 
burden on school personnel for enforcement, and supply of the vaccine (CDC, 2014). The CDC 
(2014) also reported that because the HPV vaccine was first recommended for girls only, many 
states did not want to put into action a requirement that would only apply to half of their student 
population. However, since the CDC now currently recommends that all children, male and 
female, receive a three-dose series of the vaccination starting at 11 or 12 years old, it may be 
time for the states to revisit their policies of not making HPV vaccination a requirement.  
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Also, in regards to the three-dose series, many patients and families may not be able to 
complete all three doses due to financial or logistical reasons. While receiving one or two doses 
is better than not being vaccinated at all, healthcare providers need to stress the importance of 
completing the series and should find ways of not making the three-dose sequence a barrier to 
completion. 
HPV-related infections are common in the United States and, it is estimated that up to 79 
million people are already infected. It is also estimated that 14 million new infections will occur 
each year in people ages 15–59. Half of these new infections occur among people ages 15–24, 
making this a high-risk group. Based on this assertion, it becomes crucial to understand the 
questions that must be answered in scaling down this enormous infection rate in this group. Since 
the minimum indicated age in this risk group is 15 years, it is imperative to ascertain the 
mitigating factors that need to be adopted to avert this scenario.  
The HPV vaccine is usually administered in up to three doses over a period of six months 
to protect against HPV infections. The main HPV vaccines are Cervarix and Gardasil. The 
Gardasil type protects against anal cancer and genital warts, and is highly recommended for 
males, but can also be administered to females. These vaccines provide protection for patients 
who receive all three doses of the vaccine and have adequate time to develop immunity, well 
before they engage in sexual activities that will expose them to infections. For this reason, the 
HPV vaccine should be administered to patients in the range of 11 to 12 years of age to mitigate 
the sexual risk factors associated with the teenage life and later adolescence. For various reasons 
that may lead to some boys not getting vaccinated during this age bracket, the vaccination is 
open to other age groups ranging from 13 to 26, although for male patients the HPV vaccination 
is recommended only up to the age of 21. However, for males who engage in sexual behavior 
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with other males, or who have weak immune systems (such those suffering from HIV and other 
ailments that weaken the immune system) the vaccine should be administered up to the age of 
26, especially if the required doses have not been administered earlier. Due to the higher risks 
posed to females by HPV-related infections including cervix cancer, the vaccine is generally 
preferred for females. But as discussed earlier, the risks for males are equally troublesome. For 
this reason the research delved into the factors that affect the recommendation and administration 
of this vaccine specifically for those male patients who had sought the health services of FPs, 
PEDs, and NPs. The health practitioners were assumed to be the main avenue through which 
recommendation of the vaccine and its consequent administration would occur. In addition to 
this, it is assumed that by consenting to administration of the HPV vaccine, all the requisite doses 
were completed in the required intervals and no non-conformity was evidenced. The research 
divided the age groups in this form to cover the preferred vaccination age of 11 to 12 years, the 
high-risk ages of 13 to 17, and the ages of up to 26 years to cover those male patients who may 
have been left out, as well as those with compromised immune systems. Other assumptions made 
were on the availability of the HPV vaccine where this research assumed that the vaccine is 
always available for administration. Furthermore it is assumed that the health providers 
recommended the vaccine uniformly and sufficiently to all male patients and not just to some. It 
was also not apparent to this researcher if the health practitioners detailed the individual benefits 
of getting an HPV vaccination to the male patients, especially in regards to anal cancer and 
genital warts. Details to this effect would have served to change the perception held by the male 
patients in accepting the vaccine and having it administered to them. The ACIP has placed its 
recommendation on administering the vaccine to all girls between the ages of 11 and 12, before 
they become sexually active. It’s been imperative to enlist boys in this schedule to accommodate 
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the health risks that face them, too. In late 2011, ACIP recommended routine vaccination of 
males’ ages 11 to 12 using the quadrivalent human papillomavirus vaccine (HPV4, Gardasil). 
The state of Georgia has engaged in a public awareness campaign aimed at creating 
awareness of the existence of a vaccine that averts the occurrence of cancer. The campaign is 
designed by the Georgia Department of Public Health (DPH), and the CDS-funded MARTA 
organization has come up with awareness campaigns on HPV as a leading cause of cervical 
cancer. The campaign urges parents to talk to their doctors about vaccinating their sons and 
daughters. This policy change in approaching HPV vaccination marks a paradigm shift in the 
manner in which vaccines are administered to the public, though much more is desired such as 
making compulsory vaccinations a pre-requisite to admission to institutions of learning or access 
to vocational centers. This approach would ensure a near-100% compliance with this 
vaccination, although its introduction may face resistance from advocates of civil rights and 
freedoms. The more subtle approach taken by the Georgia authorities is more of an appeal than a 
requirement, and this may prompt the population to consider this vaccination as a mere option in 
life. This is a fact that was evidenced in the report titled “Our Collaborative Course of 
Action: Georgia’s Comprehensive Cancer Control Plan: 2013-2018.” This report was prepared 
jointly by DPH and the Georgia Cancer Control Consortium (GC3), and it called for a change in 
policy to create provisions for compulsory HPV vaccination.   
Conclusion   
The national guidelines that prescribe the recommended mode of HPV vaccine 
administration have a focus on having persons between the ages of 11 and 26 vaccinated against 
HPV. However, despite this policy requirement, health provider recommendations for this 
vaccine are low, with an average of 16.2% saying that they recommend the vaccine to their 
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patients in these age groups. This factor, accompanied by the low scores recorded in the 
administration of this vaccine and parental barriers, leads to the conclusion that there exists an 
array of missed clinical opportunities for HPV vaccination for the age groups in this survey. It is 
therefore crucial that measures be taken to address all the noted barriers to effective vaccination, 
and instruction provided to the health providers on the need to enhance recommendation of the 
HPV vaccine to their patients. The results indicate that the measures must target the health 
providers with respect to their specialty, age, and ethnic background. Emphasis should be made 
on encouraging the health providers to recommend the vaccine without waiting for 
recommendations the state authorities or the CDC.   
Limitations   
This research was conducted using secondary data obtained from Albany Area Primary 
Health Care System located in southwest Georgia that provides healthcare services in 15 
counties in the region. Data from the U.S. Census Bureau indicate that most of these counties are 
small, rural locations with significant minority populations. Thus, the findings of this research 
may not represent the entire population of regional primary healthcare providers accurately.  The 
sample size is small and the responses may be based on regional socio-cultural and socio-
economic factors, along with other regional factors. For example, religious and cultural beliefs 
that are prevalent in southwest Georgia may have influenced reporting to the survey questions. In 
this regard, there is a need for a similar, large-scale study using a larger sample size in order to 
ascertain whether the findings of this research can be generalized to the entire population.  
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